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HISTORY AND GOALS OF THE CENTER FOR ALASKA NATIVE HEALTH RESEARCH (CANHR)
The work presented here is part of a larger multidisciplinary study called CANHR.  CANHR began in 2001 and partners with Yup’ik Eskimos residing in the Yukon Kuskokwim Delta in Southwest Alaska.  CANHR began in an effort to answer why the prevalence of obesity and diabetes is increasing faster in indigenous populations compared to non-indigenous populations.  In order to answer this question, CANHR’s goals are: i) to identify behavioral, genetic, and nutritional risk factors for obesity, diabetes, and cardiovascular disease; ii) to identify gene by environment interactions (GEIs) that are involved in the etiology of obesity and diabetes; and iii) to develop and implement culturally appropriate methods to decrease obesity, diabetes, and cardiovascular disease  ADDIN EN.CITE (Boyer et al., 2005; Mohatt et al., 2007).  The goal of the work presented here was to identify candidate gene associations and GEIs that are involved in the etiology of obesity.

STUDY DESIGN: CANDIDATE GENE ASSociation STUDY
In order to identify genetic risk factors and GEIs that may be involved in the etiology of obesity, a candidate gene association study was employed.  The overall goal of a candidate gene association study is to identify polymorphisms that are more common in individuals with or without a disease.  In the case of a candidate gene association study, a gene is selected based on prior knowledge of linkage or function.  Then single nucleotide polymorphisms (SNPs) are genotyped in order to determine if a polymorphism varies between individuals with different disease states (Balding, 2006).  

One shortcoming of candidate gene association studies is they often do not include GEIs.  If genetic and environmental factors are involved in the same causal pathway of disease, not including the environmental factor in a candidate gene association analysis can lead to false-negatives (Moffitt et al., 2005).  Therefore, this study sought to identify a biologically plausible environmental factor that may influence the expression of several genes that are thought to modify obesity phenotypes.

Thesis Organization




CHAPTER 1 GENERAL INTRODUCTION
1.1 OBESITY DEFINITION	
Obesity is defined as having a body mass index (BMI) of 30 (kg/m2) or more.  Since 1980 the prevalence of obesity in United States adults, age 20 or older, has doubled.  Similar increases in obesity have been observed worldwide.  Currently, in the United States, approximately 2/3 of adults are overweight (BMI ≥ 25) or obese (BMI > 30)  ADDIN EN.CITE (Barak et al., 1999; Montague and O'Rahilly, 2000; Ogden et al., 2006; Ryo et al., 2005).  Obesity is a risk factor for many chronic diseases including Type 2 diabetes (T2D), hypertension, and coronary heart disease (Malnick and Knobler, 2006).  The consequences of obesity result from excess body fat (especially in the abdominal area), not just excess weight, and the two are not equivalent.  Excess body fat is defined as percent body fat (PBF) over 25% for men and 35% for women.  Among ethnic groups, the relationship between BMI and PBF is not consistent (Deurenberg et al., 1998).  For example, at the same BMI Asians have 3-5% more body fat compared to Caucasians.  Some of the difference in PBF between ethnic groups can be attributed to differences in body build, such as trunk-to-leg-length ratio.  Because of these problems, BMI is not the best method to compare obesity between ethnic groups (Deurenberg et al., 2002).
1.2 AIM OF THE CURRENT STUDY
Obesity is a multifactorial disease, which means multiple genes and environmental variables are involved in producing the obesity phenotype.  Genes and environmental variables commonly do not work in isolation and interactions between the two are responsible for an individual’s phenotype (Loos and Bouchard, 2003).  Gene by environment interaction (GEI) studies provide a means of determining if a person’s phenotype depends on the combined effects of an environmental exposure and genotypic background (Moffitt et al., 2005).  By including an environmental variable, a more accurate estimation of population-attributable risk and a more complete understanding of disease mechanisms can be obtained (Hunter, 2005).  Yup’ik Eskimos have traditionally consumed a diet high in omega-3 polyunsaturated fatty acids (PUFAs), particularly EPA and DHA (Bersamin et al., 2007).   PUFAs, such as EPA and DHA, are known to affect the expression of several genes (Clarke, 2000).  Due to these two observations, it was hypothesized that PUFAs might be an important environmental factor to consider with regard to an individual’s risk of being obese.  

Based on the fact that EPA and DHA are known to affect the expression of several genes, I hypothesized that there would be gene by environment interactions between EPA and DHA and SNPs in candidate genes for obesity.  The three candidate genes selected for this study were: adiponectin (ADIPOQ), peroxisome proliferator activated receptor gamma (PPARG), and peroxisome proliferator activated receptor gamma coactivator 1 alpha (PPARGC1A).  Overall, consumption of high amounts of omega-3 PUFAs is hypothesized to be protective against development of obesity or obesity related diseases.  One reason for this is the potential for omega-3 PUFAs to interact and affect the expression of several candidate genes for obesity, such as ADIPOQ, PPARG, and PPARGC1A.       

1.3 CENTER FOR ALASKA NATIVE HEALTH RESEARCH (CANHR) BACKGROUND
One goal of CANHR is to understand the genetic risk factors and interactions with environmental factors for obesity, diabetes, and cardiovascular disease.  CANHR works with Yup’ik Eskimos residing in the Yukon Kuskokwim Delta in Southwest Alaska.  The area of study is about the size of Oregon and encompasses about 22,000 Yup’ik Eskimos (Boyer et al., 2007a)  There are approximately 50 rural villages and one regional center in the Yukon Kuskokwim Delta.  Of these communities, 10 are enrolled in CANHR.  The prevalence of individuals who are overweight and obese in the CANHR sample is roughly equivalent to the rest of the United States based on NHANES III data (Hopkins and Boyer pers. comm.).  For example, 64.5% of participants were overweight or obese, and the average BMI was 28.1 compared to 27.0 from NHANES III (Boyer et al., 2005; Mohatt et al., 2007).  However, the distribution of body fat differs between Yup’ik Eskimos and NHANES III.  Overall, Yup’ik women are more obese, have a larger waist circumference, and have more body fat than Yup’ik men.  Also Yup’ik women are more obese compared to women from NHANES III.  A large waist circumference suggests that an individual has large deposits of visceral fat, or fat deposited around organs in the abdomen.  For the metabolic syndrome, which is a collection of traits that are risk factors for T2D and cardiovascular disease (Boyer et al., 2007b), one risk factor is an elevated waist circumference which for women is >35 inches and for men is >40 inches (National Cholesterol Education Program (NCEP) expert panel on detection, 2002).  An elevated waist circumference is the most common risk factor for metabolic syndrome.  However, both Yup’ik women and men have lower prevalence of metabolic syndrome compared to NHANES III.  Waist circumference is also a risk factor for the development of T2D.  Yup’ik Eskimos have a historically low prevalence of T2D but over the past 13 years they have seen the largest percentage increase, 119%, compared to other American Indians (82%) and the entire US (75%)  ADDIN EN.CITE (Boyer et al., 2007b; Hopkins et al., 2007; Hopkins et al., submitted).

CANHR has employed a community-based participatory research (CBPR) design.  This framework involves research participants as co-researchers from development of the research question to dissemination of research progress and results.  With this design in mind, CANHR researchers met and gained approval from the Yukon-Kuskokwim Health Corporation (YKHC), tribal council, and communities before research began.  Early in the project, community members had the opportunity to participate in a workshop to better understand the research.  Throughout the research communities have had important roles.  All aspects of research, including any change in methods, research focus, or method of dissemination must be obtained from the YKHC before the changes can be implemented.  One example of how the community is involved in research is that the YKHC must review and approve all manuscripts and presentations before they are released.  In keeping with the CBPR approach, all results are periodically presented back to the participating communities in both English and locally spoken Yup’ik during a community meeting.  Trust is maintained and built by a close relationship between the YKHC, community leaders and members, and CANHR scientists.  Part of this trust is based upon CANHR scientists continued and repeated visits and presentations to communities.  Working with the CBPR design as a guide, CANHR scientists and Yup’ik communities have built a relationship based on trust that, ultimately, will benefit community members as well as the general population (Boyer et al., 2005; Boyer et al., 2007a; Mohatt et al., 2007).
1.4 HERITABILITY OF OBESITY
The recent rise in obesity can be attributed to many factors.  The two main factors often cited for increased obesity are increased food consumption (energy intake) and decreased physical activity (energy expenditure) (Loos and Bouchard, 2003).  Other factors such as smoking, psychoactive agents, and decreased sleep have all been found to be associated with increased obesity  ADDIN EN.CITE (Bray and Champagne, 2005; Keith et al., 2006).  Additionally, epigenetic factors are thought to be important in many chronic diseases including obesity.  Epigenetics refers to heritable changes in gene expression that do not affect DNA sequence.  Common epigenetic factors include DNA methylation and chromatin packaging.  Exposure to various environmental factors can produce an epigenetic response that can be inherited through meiosis or transgenerationally through somatic cells (Dolinoy et al., 2007; Jirtle and Skinner, 2007).  Genetic factors also contribute to the development of obesity (Speakman, 2004).  Heritability studies have been performed to determine the influence of genetics on obesity.  Heritability measures how much of a trait can be explained from genetics.   From twin, adoption, and family studies, heritability estimates from 5-90% were found.  Overall, heritabilities have clustered around 70% (Loos and Bouchard, 2003).  From these studies, it was concluded that genetics plays a major role in the development of obesity.  The search for genes that contribute to obesity has revealed at least 127 candidate genes.  However, only 22 of these candidate genes have been replicated in 5 or more studies (Rankinen et al., 2006).    
1.5 QUANTIFYING OBESITY
Quantifying the percent body fat (PBF) and the distribution of body fat (BF) of an individual can be more informative than examining weight alone.  This is because the location, type, and amount of fat influence many physiological processes such as glucose absorption.  There are three general ways to measure body composition which are direct, indirect, and doubly indirect.  Direct methods measure the variable of interest directly, indirect methods use constants and other rules to infer the variable based on direct measurements, and doubly indirect methods are based on a statistical correlation (Deurenberg and Deurenberg-Yap, 2003).  Direct measures such as magnetic resonance imaging (MRI), computer-assisted tomography scanning (CT), and dual energy X-ray absorptiometry (DEXA) are the most accurate methods to obtain PBF and BF distribution  ADDIN EN.CITE (Coppini et al., 2005; Pietrobelli et al., 2005).  MRI and CT are both considered references for quantifying total BF.  In a study by Boyer et al. (2004) that used MRI as the reference measurement, indirect and doubly indirect methods such as bioimpedance analysis (r=0.92) and anthropometrics (r=0.94) were highly correlated with MRI.  For studies that cannot afford direct methods to measure BF, such as an MRI or CT, and that are located in remote locations, this study demonstrated that anthropometrics and bioimpedance can be used to estimate adipose tissue mass (Boyer et al., 2004).

BMI is the most commonly used measure of obesity, because it is inexpensive and easy to obtain.  BMI is a doubly indirect method that is based on height and weight (Deurenberg and Deurenberg-Yap, 2003).  BMI is calculated by measuring weight in kilograms and dividing by height in meters squared.  This ratio, also referred to as the Quetelet index, is statistically correlated with body fat.  Generally, an increase in BMI indicates an increase in body fat (Kuczmarski and Flegal, 2000).  However, since being overweight does not always imply that a person has excess body fat, BMI is not the best method to determine PBF and it does not give any indication of the location of body fat (BF).  BMI is also dependent on age, gender, and ethnicity, which make setting cutoffs for BMI that correlate with PBF difficult  ADDIN EN.CITE (Deurenberg and Deurenberg-Yap, 2003; He et al., 2001).  In order to obtain a more accurate representation of the amount and location of BF, bioimpedance analysis and anthropometrics were also ascertained in the CANHR study.

Indirect measures that give a more accurate estimation of body fat than BMI include bioimpedance analysis and anthropometrics (Coppini et al., 2005).  Bioimpedance analysis is an accurate, non-invasive, low maintenance, procedure to estimate total body weight, fat mass, and free fat mass.  This method is based on the assumption that the body resembles a cylindrical conductor.  Electrodes generate an electric current that flows through the body and fat mass and hydration affect the speed the current flows through the body.  Extremities, such as arms and legs, contribute to resistance more than the abdomen, and as obesity increases the precision of bioimpedance analysis decreases.  Bioimpedance analysis is considered accurate for measuring fat mass of people with a BMI of 34 or less (Coppini et al., 2005).

Anthropometric methods, such as skin folds, waist-to-hip ratio, and waist circumference, are additional methods of estimating location and amount of body fat of an individual (Brodie and Stewart, 1999).  This method has been determined to be more accurate than BMI but less accurate than dual energy x-ray absorptiometry (Erselcan et al., 2000).  The amount of subcutaneous fat is estimated by skinfolds which are assumed to reflect total body fat (Brodie and Stewart, 1999).  In severely obese individuals anthropometrics can physically be difficult to perform.  Also, there are fewer reference populations to develop equations to relate skinfolds and body fat for severely obese individuals.  Overall, anthropometrics may become less accurate for severely obese individuals (Das, 2005).  However, if a study is primarily focused on relative differences between individuals and the relationship with a disease, this loss in accuracy may be tolerable (Boyer, pers. comm.).

Overall, for clinical use and for use in remote settings, bioimpedance analysis and anthropometric methods provide additional information such as PBF and BF distribution compared to BMI, which only offers information on a height to weight ratio that is statistically correlated with PBF.  Therefore, in the CANHR study, PBF and BF distribution were assessed using bioimpedance analysis and anthropometrics in addition to BMI.
1.6 OBESITY PHENOTYPE
Increased adipocyte, or fat cell, size and number have been correlated with obesity  ADDIN EN.CITE (Angel, 1978; Anghel and Wahli, 2007; Hirsch and Batchelor, 1976) ADDIN EN.CITE <EndNote><Cite ExcludeAuth="1" ExcludeYear="1"><Author>Hirsch</Author><Year>1976</Year><RecNum>61</RecNum><record><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="zd5srw2pcwf2zmexe5bvt5d5s2f9zvtwvrf5">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hirsch, J.</author><author>Batchelor, B.</author></authors></contributors><titles><title>Adipose tissue cellularity in human obesity</title><secondary-title>Clin Endocrinol Metab</secondary-title></titles><periodical><full-title>Clin Endocrinol Metab</full-title></periodical><pages>299-311</pages><volume>5</volume><number>2</number><edition>1976/07/01</edition><keywords><keyword>Adipose Tissue/*pathology</keyword><keyword>Adult</keyword><keyword>Age Factors</keyword><keyword>Body Weight</keyword><keyword>Cell Count</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hyperplasia</keyword><keyword>Hypertrophy</keyword><keyword>Lipid Metabolism</keyword><keyword>Male</keyword><keyword>Obesity/*pathology</keyword></keywords><dates><year>1976</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>0300-595X (Print)</isbn><accession-num>1085232</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=1085232</url></related-urls></urls><language>eng</language></record></Cite></EndNote>.  Adipocytes were first thought to primarily be involved in fat storage and fatty acid release in adipose tissue.  However, with the discovery of hormones secreted primarily from adipocytes (adipokines), adipose tissue is now considered an important endocrine organ .  There are two types of adipose tissue, white adipose tissue (WAT) and brown adipose tissue (BAT).  Both have been found to secrete many adipokines involved in regulating fat mass and nutrient homeostasis (Trayhurn and Beattie, 2001).  WAT can be further subdivided into visceral and subcutaneous fat, each with unique roles.  Overall, subcutaneous fat acts more to store fat, and visceral fat acts more as an endocrine organ.  

There are two types of subcutaneous fat, a superficial layer and a deep layer (Rosen and Spiegelman, 2006).  Subcutaneous fat is deposited throughout the body underneath the skin  ADDIN EN.CITE (Despres and Lemieux, 2006; Leibel et al., 1989).  Individuals who exhibit a “pear shape” have a large amount subcutaneous fat in their lower body (Anghel and Wahli, 2007).  There are two types of visceral fat, intraperitoneal and retroperitoneal.  The intraperitoneal type is divided into omental, mesenteric, and epididymal (Leibel et al., 1989).  Visceral fat is deposited in the upper body in the abdominal cavity.  Therefore, organs such as the liver, heart, and skeletal muscle are in close proximity to visceral fat and may even accumulate visceral fat deposits (Anghel and Wahli, 2007).  Individuals who exhibit an “apple shape” have a large amount of visceral fat in their upper body (Despres and Lemieux, 2006).   





Figure 1 1: Glucose fatty acid cycle.  
Oxidations of FFAs culminate in the formation of acetyl-CoA.  Acetyl-CoA then moves to the TCA cycle and results in increased citrate concentrations as well as increased NADH and ATP formation.  NADH and ATP prevent pyruvate from forming by inhibiting pyruvate dehydrogenase (PHD).  Citrate inhibits phosphofructokinase (PFK) which results in a build up of glucose-6-phosphate.  Glucose-6-phosphate acts to inhibit hexokinase (HK) which prevents glucose from entering glycolysis.  Glucose levels therefore remain high in the cell and prevent glucose from being transported into the cell from the plasma.  Increased glucose in the plasma results in increased insulin production.  From Frayn, 1996 and http://www.endotext.org/neuroendo/neuroendo5c/neuroendo5c.html (​http:​/​​/​www.endotext.org​/​neuroendo​/​neuroendo5c​/​neuroendo5c.html​)

In support of this idea visceral fat mass has been correlated with glucose intolerance and elevated amounts FFAs in the plasma.  Also, when FFAs are decreased, insulin action is increased  ADDIN EN.CITE (Frayn, 2000; Jensen, 2006; Miles and Jensen, 2005) ADDIN EN.CITE <EndNote><Cite ExcludeAuth="1" ExcludeYear="1"><Author>Jensen</Author><Year>2006</Year><RecNum>69</RecNum><record><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="zd5srw2pcwf2zmexe5bvt5d5s2f9zvtwvrf5">69</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Jensen, M. D.</author></authors></contributors><auth-address>Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, MN 55905, USA. jensen@mayo.edu</auth-address><titles><title>Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model</title><secondary-title>Obesity (Silver Spring)</secondary-title></titles><periodical><full-title>Obesity (Silver Spring)</full-title></periodical><pages>20S-24S</pages><volume>14 Suppl 1</volume><edition>2006/04/29</edition><keywords><keyword>Fatty Acids, Nonesterified/blood/*metabolism</keyword><keyword>Humans</keyword><keyword>Intra-Abdominal Fat/metabolism/pathology/*physiology</keyword><keyword>Lipolysis/*physiology</keyword><keyword>Metabolic Syndrome X/*metabolism</keyword><keyword>Obesity/blood/*metabolism</keyword></keywords><dates><year>2006</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1930-7381 (Print)</isbn><accession-num>16642959</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=16642959</url></related-urls></urls><electronic-resource-num>14/suppl_2/20S [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>.  Another mechanism that may cause visceral fat to affect insulin sensitivity is differences in adipocytokines released from visceral fat.  For example, leptin is secreted less by visceral fat compared to subcutaneous fat.  If fat is deposited as visceral fat, the release of leptin will be lower.  Consequently, the effect of leptin to decrease energy input will decrease and fat accumulation and insulin resistance may increase (Frayn, 1996).  Both these hypotheses suggest that visceral fat leads to insulin resistance.  It is also possible that insulin resistance could be the cause of increased visceral fat.  Insulin resistance could cause increased visceral fat if after subcutaneous fat became insulin resistant fat storage was directed towards visceral fat.  Additionally, the relationship between visceral fat and insulin resistance may be due to some other biological process (Frayn, 2000).  Overall, it seems that upper-body fat, especially visceral fat, is associated with insulin resistance and other obesity related complications.  However, the exact mechanisms remain to be elucidated.   
1.7 OBESITY AND OMEGA-3 POLYUNSATURATED FATTY ACIDS




Chapter 2 Identification of candidate genes and SNP selection
2.1 Basics of association and GEI studies
The overall goal in the selection of the candidate genes in this study was to determine whether one or more of the SNPs chosen was associated with obesity traits.  For studies of quantitative traits an association is confirmed if a polymorphism is found to correlate with a phenotype (Hirschhorn and Daly, 2005).  The polymorphism could be the causal allele or more likely is in linkage disequilibrium (LD) with the causal mutation (Cardon and Bell, 2001) (see Figure 4.1).  The associated polymorphism could represent an allele with a protective or risk-enhancing effect.  For example, if an allele is found to correlate with higher trait values the conclusion would be that the allele increases obesity risk (Hirschhorn and Altshuler, 2002).  

An association between a genotypic variant and a common disease such as obesity can occur for four reasons (Page et al., 2003).  One, the association is actually true because the variant is the cause of the disease.  Second, the association is a false positive due to chance.  Third, the association is due to the variant being in LD with the causal variant as just mentioned (Figure 2.1).  Fourth, the association is due to bias, such as procedural errors.  Additionally, for complex traits such as obesity there are likely multiple genetic and/or environmental factors that contribute to the phenotype.  Therefore, moving from an association to determining the cause of a disease is complex and requires comprehensive understanding of the disease process.  Even without knowing the true cause of a disease, it may be possible to prevent cases of a disease by blocking contributing factors  ADDIN EN.CITE (Rothman and Greenland, 2005).  Therefore, typically it is preferable to select SNPs in candidate genes that might alter the amino acid sequence of the protein or affect expression levels where the association with disease can be physiologically explained and hopefully therapeutically targeted in the future (Hirschhorn and Altshuler, 2002).  Therefore, for this analysis, SNPs were investigated that altered an amino acid sequence of the protein or that potentially may affect the transcription or translation, and hence expression, of the candidate gene of interest.  





Figure 2 1: Genetic basis of association studies.
In the top half the figure, each horizontal rectangle represents one individual and each shade represents their unique haplotype.  The star represents the causal mutation that occurs in a specific haplotype.  Any SNP in this haplotype will be in LD with the causal mutation and can be used as a marker for the causal mutation.  However, recombination is always occurring and disrupting haplotype blocks.  After 20 generations the four original haplotypes are present in each descendent.  The causal mutation is present in some individuals within part of the original haplotype.  However, each individual has different amounts of the original haplotype surrounding the causal mutation.  Modified from Cardon and Bell 2001 and Roeder 2005.

As noted, most researchers acknowledge that multi-factorial diseases, such as obesity, are the result of numerous genetic and environmental factors.  If genetic and environmental factors are involved in the same causal pathway of disease, not including the environmental factor in a candidate gene association analysis can lead to false-negatives (Moffitt et al., 2005).  In addition to including the environmental factor, including possible interactions between genetic and environmental factors is important.  Kelada et al. (2003) gave two main reasons why including gene by environment interactions (GEIs) in an association study is important.  The first is that it is possible to detect different levels of risk in a population.  In other words, ignoring GEI can result in an incorrect estimate of population attributable risk.  Population attributable risk refers to the incidence of disease that could be prevented if a factor were eliminated (Vineis and Kriebel, 2006).  The second reason is that a better understanding of the etiology of the disease can be achieved by knowing whether or not there are GEIs.  Identifying true GEIs can foster the development of interventions that can improve population health (Khoury et al., 2005).

There have been many definitions of GEI presented.  One definition that seems to summarize GEI best is that GEI is the environmental dependency of a genotype to be expressed (Guo, 2000). GEI can have different meanings depending on the context.  Four concepts of GEI were described by Grigorenko (2005).  The first was an evolutionary view of GEI that focuses on an organism’s ability to adapt to new environments.  The second is related to genetic susceptibility.  This refers to an organism’s reaction to an environmental factor that is dependent on their genotype.  The third was based on most studies of GEI being performed in laboratory animals where both the genotype and environmental exposure can be controlled and manipulated.  The last was a statistical view that focuses on non-additive effects between genetic and environmental factors to explain GEI.  

Because there are numerous types of interactions that are theoretically possible, a distinction has been made between a biological GEI and a statistical GEI  ADDIN EN.CITE (Clayton and McKeigue, 2001; Yang and Khoury, 1997).  Often, a statistically significant result is not biologically significant.  Therefore, it is possible that an interaction may be statistically significant but may not significantly influence a biological process.  In terms of GEI, a biological interaction is defined as two factors that are involved in the same mechanism and promote disease development (Yang and Khoury, 1997).  An example of this is the action of PUFAst as ligands for PPARG.  In this example the two factors are PUFAs (an environmental factor) and PPARG (a genetic factor).  Statistical interaction is defined as the differential effect of environment on disease risk in people with different genotypes (Ottman, 1996).  Two models, additive and multiplicative, are used to determine whether there is a statistical interaction (Clayton and McKeigue, 2001).  Depending on the study design, departure from either an additive or multiplicative model indicates a statistical interaction.  One can consider an interaction additive if the gene and environment act as independent risk factors for the disease, and the sum of their risks is greater than the risk associated with each factor alone; for a multiplicative interaction gene and environment act together in some way rather than independently to increase risk for disease. 







Figure 2 2: Models of GEI
Five biologically plausible models of how a genotype and environmental risk factor could interact to increase disease risk.  From Ottman 1996.

2.2 Background on gene and SNP selection
2.2.1 Justification FOR a CANDIDATE GENE STUDY
There are two main approaches for determining which genes are involved in a multi-factorial disease such as obesity.  One is a candidate gene study, and the second is a genome-wide scan.  A candidate gene study is a hypothesis driven study based on two possible criteria.  The first step for a candidate gene study is a gene selected on the basis of evidence that the gene is involved in the pathogenesis of the disease.  Selecting a gene involved in insulin secretion to determine if it involved in the pathogenesis of T2D is an example of this criterion.  This type of study is referred to as a candidate gene association study.  Association studies are founded on a statistical correlation between a genotype and a phenotype.  The second step is a set of selected genes that are under a previously reported linkage peak, also referred to as a quantitative trait loci (QTL) (Das, 2006).  A linkage peak, or QTL, is the result of a genome wide scan and identifies a DNA region associated with the phenotype under examination.  QTL studies are derived from the idea that a particular marker will co-segregate with a phenotype (Hirschhorn and Daly, 2005). 

A genome wide scan is also based on one of two criteria and results in the identification of a QTL.  The first is rooted in linkage mapping, and the second is based on a genome-wide association (GWA) study.  Linkage mapping is founded on typing genetic markers in families in order to make a genetic map, then to identify regions that are associated with a disease.  A region that shows linkage is likely to harbor a causal variant of the disease.  GWA studies are rooted in genotyping a dense set of pre-selected markers, often SNPs, distributed throughout the genome.  The goal, like other association studies, is to find a region of the genome that is associated with a disease.  So far, most studies that have located a gene involved in a complex disease have been based on candidate-gene association studies (Avise, 2004).  

For this study, we decided a candidate-gene association study would be most appropriate because we wanted to examine the hypothesis that omega-3 PUFAs affect obesity phenotypes (criterion 1 of a candidate gene study).  Therefore, I wanted to look at specific genes involved in obesity phenotypes that are also modified by PUFAs.  Additionally, there have been numerous linkage and GWA studies that have identified QTLs for obesity phenotypes.  I used the results of previous studies that identified QTLs to prioritize which genes to examine in this study (criterion 2 of a candidate gene study).   
2.2.2 DEFINITION AND IMPORTANCE OF SNPs
DNA consists of two strands of nucleotides composed of adenine (A), thymine (T), cytosine (C), and guanine (G).  Each chromosome consists of one long piece of double stranded DNA wrapped around proteins.  Human cells contain 22 pairs of autosomal chromosomes plus 2 sex chromosomes.  One of each chromosome is inherited from each parent.  A locus represents a location of a nucleotide (or nucleotides) on a chromosome.  Frequently at a locus, the same nucleotide is present in the entire population.  Single nucleotide polymorphisms (SNPs) represent a locus where different nucleotides, called alleles, are present in a population.  Frequently, distinctions between SNPs are classified based on the frequency of the less common allele.  A common distinction is to classify a variable locus as a SNP, and not a rare mutation, if the minor allele has a frequency of 1% or greater in a population.  There can be more than 2 alleles for a SNP but this is extremely rare.  SNPs are the most common form of genetic variation and are present approximately every thousand base pairs in human populations.  There are estimated to be around 10-15 million SNPs in the human genome (Hirschhorn and Daly, 2005).  SNPs can cause two types of changes related to amino acids synonymous and non-synonymous.  Synonymous SNPs do not change the amino acid which is included in a protein.  Non-synonymous SNPs change which amino acid is incorporated in a protein.  Non-synonymous SNPs are more likely to be harmful since they can change a protein’s structure and function.  Because of this, non-synonymous SNPs are often selected against and are therefore less common due to their damaging consequences.  Silent SNPs which include synonymous SNPs as well as SNPs that are in introns, promoters, or other regions do not alter a protein’s amino acid structure but may contribute to disease in other ways.  Synonymous SNPs may alter gene expression by altering the transcription of a gene.  Another possible mechanism is that synonymous SNPs may cause altered translation rates which would affect protein folding and function.  Additionally, mRNA stability and splicing could be affected by synonymous SNPs  ADDIN EN.CITE (Chamary et al., 2006; Kimchi-Sarfaty et al., 2007).  






Figure 2 3: SNPs as biomarkers.
Allele 1 of the SNP can be used as a biomarker for the disease phenotype because it is in direct association with the causal locus.  Modified from Gaut and Long 2003.

LD can be quantified with multiple measurements.  The most common measurements are denoted D, D’, and r2.  In order to calculate D, imagine the following scenario.  Consider two loci on a chromosome.  At locus 1, the base can either be an A or a C.  At locus 2, the base can either be a G or a T.  Denote the proportion of chromosomes in the population with an A at the first locus by p1A, and the proportion of chromosomes in the population with a G at the second locus by p2G.  If there were no association between the alleles at the two loci, the proportion of chromosomes in the population with both an A at the first locus and a G at the second locus would simply be the product (p1A)·(p2G).  Thus, if we denote the actual proportion of chromosomes in the population with both an A at the first locus and a G at the second locus by p1A2G, a natural measure of the association is the difference D =  p1A2G - (p1A)·(p2G).  The possible range of values of D is heavily dependent on the frequencies of the alleles at the two loci, so it is common to normalize this value by dividing by its largest possible absolute value.  The resulting measure can take on any value in the range -1.0 to 1.0, and is denoted D’.  

A value of 1.0 for D’ can be misleading.  Let’s say that in the population described above all chromosomes with an A at the first locus have a G at the second locus; but among chromosomes with a C at the first locus, there are equal numbers of chromosomes with G or T at the second locus.  The value of D’ in this situation is 1.0, the highest possible value.  In this case, if we know that the allele at the first locus is A, we definitely know the allele at the second locus.  However, if we know the allele at the first locus is C, we have no knowledge of the allele at the second locus.  In this sense, although the value of the LD measure is the highest possible, it is not “complete”.  Another measure of LD, called r2, does not suffer from this shortcoming.  This is calculated by taking the square of D, and dividing it by the frequencies of both alleles at the first locus and both alleles at the second locus.  The value of r2 is 1.0 only when knowledge of the allele at the first locus will predict the allele at the second locus without question (Gaut and Long, 2003).





Figure 2 4 Theory of haplotypes and tag SNPs.






Figure 2 5: Haploview LD.
This figure shows the amount of linkage disequilibrium between SNPs in 20kb of adiponectin that was downloaded from HapMap build 35 for CEU.  The settings in Haploview were set to show r2 values.  The higher the number and the darker the diamond, the more LD there is between two SNPs.  For example, there is more LD between two SNPs that have a diamond that is dark with 85 written than a light diamond with 10.  The following is an example of how to determine the amount of LD between two SNPs.  Begin with the SNPs rs17300539 (3) and rs16861210 (9). From both points 3 and 9, move diagonally down until the lines intercept.  This interception is labeled 78.  Haplotypes are marked blocks; here there are two haplotype blocks.

The ideal populations for locating causal loci for a disease using LD are thought to be recently founded by a small number of individuals, and have had minimal admixture.  A population that meets all these criteria would be relatively isolated, and have less allelic and locus heterogeneity.  This is important because heterogeneity from recombination makes it more difficult to locate a region that contains a causal locus.  Higher levels of LD exist in populations that were recently founded compared to “older” populations, and such large spans of LD would be beneficial in locating a region harboring a causal locus.  After a region is identified, older populations may be more useful in fine mapping the location of the causal locus  ADDIN EN.CITE (Arcos-Burgos and Muenke, 2002; Jorde, 2000).

2.2.3 Relationship between ADIPOQ, PPARG, and PPPARGC1A




Figure 2 6: Relationship between ADIPOQ, PPARG, and PPARGC1A.




The chromosomal region at 3q27 has been implicated in many studies of quantitative trait loci (QTLs) with numerous obesity phenotypes in multiple populations  ADDIN EN.CITE (Kissebah et al., 2000; Lewis et al., 2005; Luke et al., 2003; Pollin et al., 2005; Vionnet et al., 2000; Wu et al., 2002).  These studies suggest that genes at 3q27 contribute to obesity.  Adiponectin (ADIPOQ) is one of many genes that are located at 3q27  ADDIN EN.CITE (Saito et al., 1999; Takahashi et al., 2000) and has a heritability estimate of 46%  ADDIN EN.CITE (Comuzzie et al., 2001) ADDIN EN.CITE .
2.3.2 Adiponectin DNA and amino acid structure
Adiponectin was discovered independently by four groups in the mid 1990s  ADDIN EN.CITE (Hu et al., 1996; Maeda et al., 1996; Nakano et al., 1996; Scherer et al., 1995).  Subsequent work showed that the nucleotide sequence spans 16 kb, there are three exons and two introns, and the promoter lacks a TATA box which is shown in figure 2.7  ADDIN EN.CITE (Saito et al., 1999; Takahashi et al., 2000).  The protein product of adiponectin is 244 amino acids in humans.  It is composed of a secretary signal sequence, a non-collagenous sequence, a collagen like sequence that is composed of Gly-X-Y, and a C-terminal sequence that is similar to collagen X, VIII, and C1q.  Figure 2.8 shows the domains in ADIPOQ.  ADIPOQ is homologous to members of the collagen superfamily and, similarly, is found in complexes.  Homo-oligomeric complexes of adiponectin take the form of trimers, hexamers, and high molecular weight (HMW) oligomers  ADDIN EN.CITE (Tsao et al., 2003).  There are eight isoforms of adiponectin present in the human body.  These forms are dependent on the hydroxylation and glycosylation of four conserved lysine residues  ADDIN EN.CITE (Wang et al., 2002). 

Figure 2 7: Adiponectin gene representation.




Figure 2 8: Adiponectin amino acid domains.
Section 1 corresponds to the signal sequence of adiponectin.  Section 2 corresponds to the Gly-X-Y repeat region and section 3 corresponds to the c-terminal region that is homologous with collagen.  Modified from Tsao et al. 2003.
2.3.3 Adiponectin location
Adiponectin is an adipokine produced primarily in adipocytes and found in plasma at concentrations of 1.9-17μg/ml in healthy individuals.  Arita et al. (1999) examined mean adiponectin level in 57 obese and 87 non-obese individuals.  They found mean adiponectin to vary from 3.7 μg/ml for obese individuals and 8.9 ug/ml for non-obese individuals  ADDIN EN.CITE (Arita et al., 1999).  Similarly, for Yup’iks in the CANHR study, the mean adiponectin level for obese and nonobese individuals was 7.8 μg/ml and 10.8 μg/ml, respectively (unpublished data).  Adiponectin accounts for 0.01% of total plasma protein, which is three orders of magnitude higher than most serum hormones (Ukkola and Santaniemi, 2002).  Full length adiponectin (trimers and hexamers) are most commonly found in the plasma (Saito et al., 1999).  Omental (visceral) adipose tissue secretes more adiponectin than does subcutaneous adipose tissue.  The adiponectin that is secreted from omental tissue is negatively correlated with BMI  ADDIN EN.CITE (Motoshima et al., 2002).  
2.3.4 Adiponectin roles
Adiponectin has three main roles in humans.  One role of adiponectin is to promote cell proliferation and differentiation from preadipocytes to adipocytes.  A second is to regulate gene expression of genes involved in adipogenesis.  Adiponectin acts through two receptors, either ADIPOR-1 or ADIPOR-2.  Once in a cell, adiponectin increases the expression of genes involved in adipogenesis (Diez and Iglesias, 2003).  One gene that has increased expression due to adiponectin is 5’-AMP-activated protein kinase.  Adiponectin has been shown to be involved in the phosphorylation of 5’-AMP-activated protein kinase.  Phosphorylation of 5’-AMP-activated protein kinase increases its expression  ADDIN EN.CITE (Yamauchi et al., 2002).   ADDIN EN.CITE Lastly, adiponectin increases the lipid content of adipocytes and insulin responsiveness of glucose transport into adipocytes  ADDIN EN.CITE (Fu et al., 2005) ADDIN EN.CITE  ADDIN EN.CITE .  Increased lipid content and insulin responsiveness results from increased beta-oxidation followed by decreased free fatty acids (FFA) in the plasma.  Reduced levels of plasma FFA are the consequence of lower intracellular levels of triglycerides in liver and muscle cells  ADDIN EN.CITE .  Increased beta-oxidation decreases insulin resistance  ADDIN EN.CITE (Yamauchi et al., 2002).  Adiponectin, therefore, acts to decrease glucose levels and increase insulin sensitivity (Kadowaki et al., 2006).  Adiponectin’s ability to depress glucose levels and increase insulin sensitivity is the outcome of insulin’s capacity to stimulate glucose uptake  ADDIN EN.CITE (Fu et al., 2005).  Increased cell proliferation, differentiation, and regulation of genes involved in adipogenesis are consequences of adiponectin being associated with increasing the expression of genes involved in adipogenesis.  Increased expression of genes involved in adipogenesis results in an increase in the synthesis of the number of adipocytes as well as the lipid content of adipocytes  ADDIN EN.CITE (Fu et al., 2005).  

Pajvani et al.  ADDIN EN.CITE (2004) demonstrated that the ratio of high molecular weight (HMW) adiponectin to total adiponectin, SA, was a better predictor of diabetes than total adiponectin.  The HMW form of adiponectin appears to be more glycosylated, allowing it to form globular structures.  The ratio of HMW to total adiponectin was higher in healthy controls compared to diabetics  ADDIN EN.CITE (Wang et al., 2006).  The HMW is more prominent in women compared to men  ADDIN EN.CITE (Diez and Iglesias, 2003; Oh et al., 2007). ADDIN EN.CITE  
2.3.5 SNPs selected for genotyping
A description of SNP nomenclature is necessary before describing which SNPs were selected for genotyping.  SNPs that are submitted to NCBI receive an “rs” number.  This number is a unique identifier for each SNP.  However, currently few SNPs are identified by their rs number in the literature.  Instead, various abbreviations are used for many SNPs.  In an effort to take this fact into account, the rs number for each SNP is presented, but the most common name in the literature is used throughout the rest of the text.

Most of the common polymorphisms in adiponectin have been previously genotyped in a smaller number of individuals (N=593) in the CANHR study using the Illumina platform (San Diego, California), as part of a large collaboration (Chung et al., in review).  The Illumina platform uses sequencing technology developed by Solexa.  The sequencing method is based on parallel sequencing using terminator-based chemistry  ADDIN EN.CITE (http://www.illumina.com).  Marginally significant results for the association of several adiponectin SNPs with obesity phenotypes in Yup’ik Eskimos were obtained; therefore we decided to sequence the exons, exon-intron boundaries, and promoter region of adiponectin in 30 Yup’ik Eskimos at the extremes of BMI.  Two additional SNPs, SNP1T>G (rs17846866) and SNP2T>G located on chromosome 3 at 188053521, were identified.  To the best of our knowledge, SNP2T>G has only been identified in Yup’iks (Boyer pers. comm.).  Since the initial association of adiponectin with 593 participants, CANHR has recruited additional participants and now has over 1000 individuals enrolled.  This increase in sample size has provided more power to detect an association.  Due to the fact that previously adiponectin had SNPs that were marginally significant and two SNPs were identified through sequencing, we decided to examine the SNPs identified through sequencing and any additional SNPs that may have been missed in the initial association.  The reason for examining all common polymorphisms in a gene was examined by Neale et al. (2004).  They suggested genotyping all the common variants in a candidate gene in order to examine all potential risk alleles.  For this study, the two SNPs identified through sequencing as well as -11391G>A (rs17300539) identified in the literature were chosen for additional genotyping to cover all the common variation in adiponectin.  Based on the results from HapMap and Haploview -11391G>T and SNP1T>G are not in LD.  SNP2T>G has not been described previously, and it is unclear if it is LD with either of the other two SNPs.
2.3.6 Adiponectin SNP -11391G>A
-11391G>A (also known as -11388G>A) has been shown to be associated with adiponectin levels in Caucasian and African American populations  ADDIN EN.CITE (Bouatia-Naji et al., 2006; Fumeron et al., 2004; Heid et al., 2006; Tanko et al., 2005; Vasseur et al., 2002; Vasseur et al., 2005).  These studies showed that the A allele is associated with higher adiponectin levels compared to the G allele.  This variant is also associated with T2D  ADDIN EN.CITE (Vasseur et al., 2002), the ratio of central fat mass and peripheral fat mass, and impaired fasting glucose  ADDIN EN.CITE (Fumeron et al., 2004).  The association between -11391G>A and adiponectin levels was strengthened when -11391G>A was in a haplotype with either -10,068 (A-G) or -11377 (G-G)  ADDIN EN.CITE (Tanko et al., 2005; Vasseur et al., 2002; Woo et al., 2006).  ADDIN EN.CITE  -11391G>A is located in the promoter and therefore does not cause an amino acid change.  However, it is located near a potential regulatory sequence and may modulate transcriptional activity  ADDIN EN.CITE (Vasseur et al., 2002).  Bouatia-Naji et al. (2006)  showed that the A allele increased transcriptional activity by 2.5 times.  
2.3.7 Adiponectin SNP1 and SNP2
SNP1T>G and SNP2T>G were found from previous sequencing (Boyer pers. com).  Both SNPs are located in intron 1, just upstream of exon 2.  30 individuals, 15 from each extreme of body weight, were selected from the CANHR dataset for sequencing.  Sequencing of the exons and exon-intron boundaries was performed by Agencourt (Beverly, MA).  Seven individuals from the 30 sequenced were heterozygous for SNP1T>G, and one individual was homozygous for the minor allele.  Three individuals from the 30 sequenced were heterozygous for SNP2T>G.  We hypothesized that since these SNPs were discovered in a candidate gene for obesity, they would be good SNPs to examine further to see if there are gene by environment interactions between omega-3 PUFAs and adiponectin.  
2.3.8 Adiponectin, fatty acids, and PUFAs
Levels of circulating adiponectin have been associated with intake of saturated fatty acids and omega-3 fatty acids in some animals ADDIN EN.CITE .  Flachs et al.  ADDIN EN.CITE (2006) demonstrated that two omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), increased the amount of plasma adiponectin regardless of food intake in mice.  They concluded that this increase was the result of adipocyte stimulation and increased adiponectin release from white adipose tissue (WAT).  Associated with increased adiponectin was a decrease in plasma triglycerides, non-esterfied fatty acids (NEFA), and insulin.  Lorente-Cebrian et al.  ADDIN EN.CITE (2006) found that EPA decreased adiponectin gene expression and the amount of protein present in rats.  Similarly, mice fed a high fat diet were found to have decreased levels of adiponectin RNA and serum protein  ADDIN EN.CITE (Barnea et al., 2006) ADDIN EN.CITE .  In CANHR, the relationship between adiponectin and EPA and DHA measured in red blood cells (RBCs) was low.  The r2 between adiponectin and EPA was 0.02 and between adiponectin and DHA r2 was 0.01 (unpublished data).  Although these results do not all agree, they do indicate that levels of adiponectin are affected by the type and amount of fat ingested.  Specifically, these studies do not agree on whether there is a positive or negative correlation between adiponectin and EPA and DHA.  
2.4 Peroxisome proliferator activated receptor gamma (PPARG)
2.4.1 PPARG QTL
Hsueh et al.  ADDIN EN.CITE (2001) performed a genome scan and found evidence for linkage between percentage body fat (PBF) and marker D353608 at 3p.  Linkage was also found between this marker and BMI, waist circumference, and serum leptin.  Lee et al.  ADDIN EN.CITE (1999) had previously found evidence for linkage with PBF at D3S1286, 2cM away from the marker used by Hsueh et al.  ADDIN EN.CITE (2001).  Both markers are near the region where PPARG resides.  These studies suggest that PPARG may be involved in the development of obesity.
2.4.2 PPARG DNA and amino acid structure
The human form of PPARG was determined by multiple groups  ADDIN EN.CITE (Elbrecht et al., 1996; Greene et al., 1995; Lambe and Tugwood, 1996) ADDIN EN.CITE . ADDIN EN.CITE  ADDIN EN.CITE   PPARG is located at 3p25, spans over 100 Kb, and is composed of nine exons  ADDIN EN.CITE (Fajas et al., 1997; Greene et al., 1995) ADDIN EN.CITE .  From the 5’ end these exons are termed A1, A2, B, and exons 1-6  ADDIN EN.CITE (Fajas et al., 1997).  Four transcripts of PPARG have been described to date, and they are termed PPARG1, PPARG2, PPARG3, and PPARG4.  The four transcripts all contain exons 1-6, but their differences are due to alternative promoters that are between exons A1, A2, and B.  PPARG1 has eight exons and its promoter is upstream of exon A1.  PPARG2 has seven exons, and its promoter is upstream of exon B.  PPARG3 has eight exons, and its promoter is upstream of exon A2.  Finally, PPARG4 has six exons, and its promoter is upstream of exon one  ADDIN EN.CITE (Fajas et al., 1997; Fajas et al., 1998; Greene et al., 1995; Sundvold and Lien, 2001).  Figure 2.9 shows the different isoforms of PPARG.






Figure 2 9: PPARG gene represenation.





Figure 2 10: PPARG amino acid domains
A/B is the signal sequence, DBD is the DNA binding domain, and LBD is the ligand binding domain.

2.4.3 PPARG location and role
PPARG is expressed in the heart, skeletal muscle, and adipose tissue (Aranda and Pascual, 2001).  High expression of PPARG is seen in both WAT and BAT, particularly the PPARG2 isoform.  PPARG2 was shown to increase adipose differentiation (adipogenesis) in vitro  ADDIN EN.CITE (Tontonoz et al., 1994).  PPARG was shown to be essential for in vivo adipogenesis and that the absence of PPARG caused lipodystrophy in mice  ADDIN EN.CITE (Barak et al., 1999; Rosen et al., 1999).  Consequently, PPARG is often referred to as the master regulator of adipogenesis ADDIN EN.CITE .  Thiazolidinediones (TZDs) are used as insulin sensitizing drugs and have been shown to activate PPARG.  Induction of PPARG by TZDs improves insulin sensitivity and glucose tolerance by increasing glucose uptake.  PPARG is also involved with signaling adipokines, such as adiponectin, to be released from adipocytes as well as lipid homeostasis.  Overall, PPARG increases adipogenesis, insulin sensitivity, lipid homeostasis, glucose metabolism, and adipokine signaling  ADDIN EN.CITE (Anghel and Wahli, 2007; Savage, 2005).
2.4.4 PPARG ligands
PPARG has been described as a fatty acid sensor ADDIN EN.CITE .  Mice fed a high fat diet have increased expression of PPARG2 in adipose tissue  ADDIN EN.CITE (Savage, 2005).  Fatty acids (FAs) and fatty acid derivatives have been found that activate PPARG  ADDIN EN.CITE (Kliewer et al., 1997).  These FAs include PUFAs such as linolenic acid (LA), alpha-linoleic acid (ALA), and arachadonic acid (AA).  EPA and DHA have also been shown to act as ligands for PPARG.  Eicosanoids, which are PUFA derivatives, have been shown to activate PPARG  ADDIN EN.CITE (Forman et al., 1995; Savage, 2005; Tontonoz et al., 1994; Zhang et al., 2007).  Synthetic molecules, such as TZDs, have also been shown to bind and activate PPARG ADDIN EN.CITE .  One fatty acid derivative, a protstaglandin termed d15PGJ2, was shown to be the endogenous mediator of PPARG  ADDIN EN.CITE (Forman et al., 1995; Kliewer et al., 1997).  However, follow-up work showed that d15PGJ2 could not be the endogenous mediator of PPARG because d15PGJ2 is made at picomolar concentrations in 3T3-L1 preadipocytes  ADDIN EN.CITE (Bell-Parikh et al., 2003).  Previous studies had used amounts of 2.5-100 uM of 15dPGJ2 to express PPARG  ADDIN EN.CITE (Bell-Parikh et al., 2003).  The search for the endogenous ligand of PPARG is ongoing.  Yamamoto et al.  ADDIN EN.CITE (2005) demonstrated that putative metabolites of DHA, such as 4-OHDHA, activated PPARG more effectively than DHA, some TZDs, and 15dPGJ2.  PPARG appears to be fairly promiscuous for ligands.  The ligand binding domain is a large hydrophobic cavity that can accept a wide range of ligands  ADDIN EN.CITE (Bouaboula et al., 2005) ADDIN EN.CITE .  It is possible that various ligands for PPARG modulate binding to the ligand binding domain of PPARG.  This binding could affect the conformation of PPARG which could affect which cofactors bind.  Ultimately, this could cause a difference in gene expression and biological response (Lehmann et al., 1995).  From all these studies fatty acids, especially PUFAs, seem to be able to regulate the expression of PPARG.
2.4.5 PPARG SNPs
Four SNPs were chosen for genotyping in PPARG.  They were His447His also referred to as C1431T (rs3856806), C-681G (rs10865710), C-2821T (rs12497191) and Pro12Ala (rs1801282).
2.4.6 PPARG SNP His447His
His447His has been found to be associated with BMI and T2D risk.  Of the two alleles, T and C, the T allele has been associated with decreased BMI  ADDIN EN.CITE (Meirhaeghe et al., 1998) and increased BMI  ADDIN EN.CITE (Doney et al., 2002; Tai et al., 2004) andwith decreased risk of T2D  ADDIN EN.CITE (Tai et al., 2004).  Larsen et al.  ADDIN EN.CITE (2005) found no association with obesity phenotypes with this allele.  This allele is located in exon 6 of PPARG and results in a synonymous mutation.  This suggests this polymorphism may be in LD with a functional mutation  ADDIN EN.CITE (Meirhaeghe et al., 1998).
2.4.7 PPARG SNP C-681G
C-681G has been associated with LDL levels.  In a haplotype that included two other polymorphisms, C-689G and Pro12Ala, the G allele of C-681G was primarily responsible for an increase in LDL levels  ADDIN EN.CITE (Meirhaeghe et al., 2005). ADDIN EN.CITE   This polymorphism is located in the promoter for PPARG3 and affects the binding of a transcription factor.  PPARG3 is normally expressed in adipocytes, the colon, and macrophages.  The transcription factor that is affected by this SNP is the signal transducer and activator of transcription factor 5B (STAT5B).  The G allele of C-681G abolished STAT5B’s ability to bind to the promoter of PPARG3, and, consequently, the activity of the PPARG3 promoter was decreased  ADDIN EN.CITE (Meirhaeghe et al., 2003).
2.4.8 PPARG SNP C-2821T
C-2821T has been associated with hepatic insulin action, fasting plasma insulin concentrations, and moderately with BMI.  C-2821T is located in the promoter for PPARG2.  Therefore, it is possible that this variant may alter gene transcription.  The T allele of this polymorphism increased transcription in vitro  ADDIN EN.CITE (Muller et al., 2003).
2.4.9 PPARG SNP Pro12Ala
The most reproducible association with T2D has been with the Pro12Ala, located in the N-terminal domain of PPARG2  ADDIN EN.CITE (Altshuler et al., 2000; Anghel and Wahli, 2007).  Pro12Ala is the result of a non-synonymous cytosine to guanine SNP at codon 12 in PPARG.  In fact, Pro12Ala is a highly replicated risk factor for T2D with a combined odds ratio (OR) of 1.2 (Anghel and Wahli, 2007). The Ala allele has been associated with decreased insulin concentrations which imply an increase in insulin sensitivity (Tonjes and Stumvoll, 2007).  The Ala allele is also associated with a decreased risk of T2D, higher BMI, and greater levels of adiponectin ADDIN EN.CITE .  It is estimated that this variant accounts for about 25% of the population attributable risk for T2D  ADDIN EN.CITE (Altshuler et al., 2000) ADDIN EN.CITE .  The Ala allele decreases the binding affinity of PPARG to promoter elements and may decrease the transactivation of target genes  ADDIN EN.CITE (Deeb et al., 1998).
2.4.10 Pro12Ala polymorphism and fatty acids
There are reasons to suspect that the Pro12Ala polymorphism modifies the association of PPARG with various environmental factors (Tonjes and Stumvoll, 2007).  The first study to examine the role of diet with Pro12Ala showed that as the polyunsaturated fatty acid to saturated fatty acid (P:S) ratio increased, individuals who were homozygous for Ala had lower BMIs compared to Pro carriers.  The amount of polyunsaturated fatty acid consumption and saturated fatty acid consumption was determined from food frequency questionnaires.  When the P:S ratio was not considered there was no difference in BMI between Pro carriers or Ala homozyogotes (Luan et al., 2001).  Another study examined the relationship between total fat and saturated fat.  When fat intake and saturated fats were taken into account there was an association between the Pro allele and BMI and waist circumference  ADDIN EN.CITE (Robitaille et al., 2003).  Fat intake was found to be positively correlated with BMI in Pro homozygotes but not in carriers of the Ala allele  ADDIN EN.CITE (Memisoglu et al., 2003).  Although there is a discrepancy in these studies, the measurement of fat intake and the types of fat studied differed.  There is likely to be biological relevance to the interaction between the Pro12Ala and fat intake  ADDIN EN.CITE (Memisoglu et al., 2003).
2.5 Peroxisome proliferator activated receptor gamma, coactivator 1 alpha (PPARGC1A) 
2.5.1 PPARGC1A QTL
Genome wide scans have identified the region between 4p15-q14 to be associated with obesity and diabetes phenotypes.  These phenotypes included, fasting plasma insulin, abdominal fat, and BMI  ADDIN EN.CITE (Arya et al., 2004; Perusse et al., 2001; Pratley et al., 1998; Stone et al., 2002).  One candidate gene in this region, PPARGC1A was suggested as a candidate gene that may explain the linkage between this region and obesity phenotypes  ADDIN EN.CITE (Arya et al., 2004; Perusse et al., 2001)  ADDIN EN.CITE .
2.5.2 PPARGC1A DNA and amino acid structure





Figure 2 11: PPARGC1A DNA representation.




Figure 2 12: PPARGC1A major amino acid domains.
From the left, 1 is the CBP/p300 and SRC-1 AD domain, 2 is the leucine-rich motif, 3 is the PPARG recognition domain, 4 and 5 are the argine-serine regions, and 6 is the RNA recognition motif.
2.5.3 PPARGC1A is a coactivator
PPARGC1A is a class II coactivator ADDIN EN.CITE .  Coactivators increase transcription rates of target genes by interacting with transcription factors .  They do not bind DNA but instead modify chromatin or associate with RNA polymerase to increase transcription ADDIN EN.CITE .  Class II coactivators cannot modify histones and have to form complexes with coregulators, such as CBP/p300 and SRC-1, to acetylate histones (Soyal et al., 2006).
2.5.4 PPARGC1A location and role
PPARGC1A is expressed in tissues with high demands for energy and that are rich in mitochondria.  These tissues include BAT, heart, skeletal muscle, kidney, liver and the brain (Puigserver and Spiegelman, 2003).  Exposure to cold increased adaptive thermogenesis, skeletal muscle and PPARGC1A expression in BAT  ADDIN EN.CITE (Puigserver et al., 1998).  Adaptive thermogenesis refers to a change in heat dispersal due to changes in temperature, nutrition, or infection (Knutti and Kralli, 2001).  In addition to cold adaptive thermogenesis, PPARGC1A also promotes mitochondrial biogenesis, hepatic gluconeogenesis, and fatty acid beta-oxidation (Soyal et al., 2006).  Expression of PPARGC1A is low in WAT, but expression of PPARGC1A was induced during preadipocyte differentiation in subcutaneous adipocytes  ADDIN EN.CITE (Semple et al., 2004; Tiraby et al., 2003).  This supports the idea that WAT can take on the functions of BAT upon PPARGC1A expression and switch from storing energy to burning energy (Knutti and Kralli, 2001).    
2.5.5 PPARGC1A SNPs
Three SNPs were chosen for genotyping in PPARGC1A.  They were Asp475Asp (rs17574213), Thr394Thr (rs2970847), and Gly482Thr (rs8192678).
2.5.6 PPARGC1A SNP Asp475Asp
In a haplotype analysis the rare allele of Asp475Asp was associated with decreased BMI, increased whole body glucose uptake and low levels of glucose after an oral glucose tolerance test  ADDIN EN.CITE (Pihlajamaki et al., 2005). 

2.5.7 PPARGC1A SNP Thr394Thr
In a haplotype with another variant (Gly482Ser), Thr394Thr was found to be associated with T2D  ADDIN EN.CITE (Hara et al., 2002).  Further work showed that the A allele caused a 1.6 fold increase in T2D.  This allele was also associated with increased cholesterol, LDL, and blood pressure  ADDIN EN.CITE (Vimaleswaran et al., 2005).  Further analysis by the same group demonstrated that the A allele was associated with an increase in total body fat including both visceral and subcutaneous fat  ADDIN EN.CITE (Vimaleswaran et al., 2006).  ADDIN EN.CITE  These results were said to be false due to genotyping error and data misinterpretation  ADDIN EN.CITE (Das, 2007).  The authors responded and concluded they made a mistake in calculating HWE and that it was not satisfied for T2D cases.  However, they did not believe this changed their results  ADDIN EN.CITE (Vimaleswaran et al., 2007).   
2.5.8 PPARGC1A SNP Gly482Ser
The Ser allele of Gly482Ser has been associated with increased fasting insulin levels, increased insulin resistance, and a relative risk of 1.34 in developing T2D  ADDIN EN.CITE (Ek et al., 2001; Hara et al., 2002).  The Ser allele has also been found to be associated with increased lipid oxidation, decreased subcutaneous adipocyte size, lower FFA, and higher levels of HDL-C  ADDIN EN.CITE (Muller et al., 2003; Vohl et al., 2005).  A meta-analysis showed the Ser allele has an OR of between 1.07 and 1.1 (Barroso et al., 2006).  Barroso et al. (2006) concluded that Gly482Ser is not associated with BMI or fasting insulin but may involve an increased risk of T2D.  The same group later showed that the Ser allele decreases the levels of PPARGC1A mRNA, raises nonesterified free fatty acids (NEFAs), and increases the risk for T2D (Franks et al., 2007).  Although the functionality of this SNP has not been determined, it is close to a putative phosphorylation site at Gly487Ser.  Domains of phosphorylation may affect the localization of PPARGC1A.  Also, this polymorphism is located near the DEAD box and may affect protein binding  ADDIN EN.CITE (Soyal et al., 2006).
2.5.9 PPARGC1A and fatty acids
Individuals who are obese, insulin resistant, or have T2D have reduced levels of PPARGC1A, particularly in skeletal muscle.  This is accompanied by a decreased mitochondrial oxidative capacity  ADDIN EN.CITE (Staiger et al., 2005).  Unsaturated fatty acids were found to stimulate the expression of PPARGC1A by 2-3 times  ADDIN EN.CITE (Staiger et al., 2005).  EPA and DHA also stimulate PPARGC1A expression, particularly in WAT of epididymal (visceral) fat  ADDIN EN.CITE (Flachs et al., 2005).  In agreement with this, long chain PUFAs additionally increase PPARGC1A expression (Staiger et al., 2006).  


CHAPTER 3 USE OF A BIOMARKER, δ15N, TO DETERMINE PUFA INTAKE.

3.1 Polyunsaturated fatty acids (PUFAS) ARE IMPORTANT IN OBESITY AND OTHER CHRONIC DISEASES
Many epidemiological and clinical studies have established an inverse relationship between consumption of n-3 PUFAs, such as EPA and DHA, from fish and mortality and coronary heart disease (Holub and Holub, 2004).  Most of the EPA and DHA in humans is obtained from marine sources of food such as salmon  ADDIN EN.CITE (Das, 2006).  Many of the effects of n-3 PUFAs have been determined from supplementation experiments with fish oil in human or animal models.  In non-human animals, fish oil has been shown to lower triglycerides, decrease weight gain, decrease body fat mass, and increase insulin sensitivity  ADDIN EN.CITE (Couet et al., 1997; Krebs et al., 2006).  Studies in humans have not all agreed whether body fat is reduced with fish oil supplementation.  Overall, most studies suggest that increased amounts of n-3 from fish oil is beneficial  ADDIN EN.CITE (Couet et al., 1997; Hill et al., 2007; Krebs et al., 2006).  
3.2 WHAT ARE PUFAS
Fatty acids (FAs) are carboxylic acids with a carboxyl group and 4-36 carbons in the hydrocarbon tail.  Types of FAs are based on chain length and the number and location of double bonds present in the hydrocarbon chain.  Saturated FAs do not contain any double bonds while unsaturated FAs contain at least one double bond.  Monounsaturated FAs (MUFAs) are a type of unsaturated FA with only one double bond present, and PUFAs are a type of unsaturated FA with 2 or more double bonds.  Short chain PUFAs contain 18 carbons or less, and long chain PUFAs contain 20 carbons or greater (Nelson and Cox, 2004).

There are multiple families of PUFAs that are based on the omega or n nomenclature.  This nomenclature is based on the terminal methyl group which is designated as the omega carbon.  The first double bond from the omega carbon is recognized as well as the appropriate sterochemistry.  This nomenclature was developed because families of PUFAs have similar effects on the body.  Also, this nomenclature distinguishes PUFAs derived from different parent FAs.  The n-3 family of PUFAs is derived from cis alpha-linolenic acid while the n-6 family is derived from cis linoleic acid.  For example, all n-3 PUFAs have a double bond between the third and fourth carbon from the omega carbon.  Figure 3.1 shows how an omega-3 PUFA is named using the omega nomenclature and figure 3.2 shows several different omega-3 and omega-6 PUFAs.  Similarly, all n-6 PUFAs have a double bond between the sixth and seventh carbon from the omega carbon  ADDIN EN.CITE (Davidson and Cantrill, 1985; Holman, 1998) ADDIN EN.CITE . ADDIN EN.CITE 

Figure 3 1: Omega nomenclature for EPA.
The carbon of the methyl group is designated as the omega carbon and is considered carbon 1.  EPA is an omega-3 PUFA because the first double bond is between the third and fourth carbon when counting from the omega carbon.


Figure 3 2: Structure of n-6 and n-3 PUFAs.







3.3 HIGH PUFA levels in ESKIMOS
3.3.1 greenland eskimos- a link between n-3 pufas and chronic disease
In the 1970s one of the first groups of studies to show a protective relationship between n-3 PUFAs such as EPA and DHA was observed in Greenland Eskimos (Demaison and Moreau, 2002).  Bang et al.  ADDIN EN.CITE (1972, 1971) ADDIN EN.CITE <EndNote><Cite ExcludeAuth="1" ExcludeYear="1"><Author>Holman</Author><Year>1998</Year><RecNum>63</RecNum><record><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="zd5srw2pcwf2zmexe5bvt5d5s2f9zvtwvrf5">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Holman, R. T.</author></authors></contributors><auth-address>Hormel Institute, University of Minnesota, Austin 55912, USA.</auth-address><titles><title>The slow discovery of the importance of omega 3 essential fatty acids in human health</title><secondary-title>J Nutr</secondary-title></titles><periodical><full-title>J Nutr</full-title></periodical><pages>427S-433S</pages><volume>128</volume><number>2 Suppl</number><edition>1998/03/21</edition><keywords><keyword>Aged</keyword><keyword>Animals</keyword><keyword>Child</keyword><keyword>Fatty Acids/blood/classification</keyword><keyword>Fatty Acids, Essential/*deficiency</keyword><keyword>Fatty Acids, Omega-3/*administration &amp; dosage/metabolism</keyword><keyword>Fatty Acids, Omega-6</keyword><keyword>Fatty Acids, Unsaturated/administration &amp; dosage/metabolism</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Infant, Newborn</keyword><keyword>Liver/*metabolism</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Nutrition Disorders/*diet therapy/etiology/metabolism</keyword><keyword>Nutritive Value</keyword></keywords><dates><year>1998</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>0022-3166 (Print)</isbn><accession-num>9478042</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=9478042</url></related-urls></urls><language>eng</language></record></Cite></EndNote> observed that Greenland Eskimos consumed a large amount of marine food rich in EPA and DHA  ADDIN EN.CITE (Das, 2006).  Even with such high fat consumption, mainly from seals, whales, fish, and seabirds, Greenland Eskimos had low rates of coronary heart disease, diabetes and other chronic disease related to a Western diet.  In further studies Bang et al. (1976) found that mainland Danes consume similar amounts of fat but had higher rates of coronary heart disease and diabetes.  Mainland Danes obtained most of their fat from dairy sources that are rich in n-6 PUFAs  ADDIN EN.CITE (Bang et al., 1976; Simopoulos, 1999; Sinclair et al., 2000).  In addition to a difference in the type of fat consumed between Greenland Eskimos and mainland Danes (n-3 versus n-6) Greenland Eskimos had relatively low plasma lipid levels and high amounts of n-3 PUFAs, particularly EPA, in their plasma (Bang and Dyerberg, 1972).  
3.3.2 IMPORTANCE OF THE RATIO BETWEEN N-3 AND N-6 PUFAs
Due to the different consequences of dietary intakes of n-6 and n-3 FAs, the ratio of n-6 to n-3 is thought to be important to health.  For example, a high ratio of n-6 to n-3 is positively correlated with T2D  ADDIN EN.CITE (Simopoulos, 1999).  Humans historically consumed an n-6 to n-3 FA ratio of approximately 1:1.  However, over the last 100-150 years this ratio has increased to 10-12:1 due to increasing amounts of n-6 incorporated in the diet (Simopoulos, 1999).  The last 40 years have seen a relatively stable ratio of between 12 or 10:1  ADDIN EN.CITE (Kris-Etherton et al., 2000; Simopoulos, 1999).  The increased ratio of n-6 to n-3 PUFAs has been implicated as a contributing factor to the rise of obesity  ADDIN EN.CITE (Krebs et al., 2006).  Recommendations for a ratio of approximately 2:1 have been suggested, but so far there is no clear recommendation in the United States  ADDIN EN.CITE (Kris-Etherton et al., 2000).

3.3.3 PUFA LEVELS IN YUP’IK ESKIMOS
Similar to Greenland Eskimos, the traditional diet of Yup’ik Eskimos in Southwest Alaska relies heavily on marine mammals and fish which are high in EPA and DHA   ADDIN EN.CITE (Bersamin et al., 2007; Das, 2006).  The traditional diet of Yup’ik Eskimos also includes berries, wild greens, game animals, and fowl.  Presumably, Yup’ik Eskimos would have similar levels of Western disease and n-3 PUFAs as Greenland Eskimos if they consume a diet that relies on foods high in n-3 PUFAs.  Although many Western foods are consumed by Yup’ik Eskimos, 22% of energy overall obtained from traditional foods (Bersamin et al., 2007).  Of this, over 90% of traditional food intake is from fish, fish roe, game meat, and game fowl, and 69% is solely from marine sources (Bersamin et al., 2007).  

Based on a diet that is high in marine foods rich in n-3 PUFAs and a low incidence of chronic diseases, one would predict that Yup’ik Eskimos have a diet that consists of large amounts of EPA and DHA.  The relative amount of EPA and DHA consumed is reflected in the levels of EPA and DHA in erythrocyte membranes  ADDIN EN.CITE (Katan et al., 1997).  In Yup’ik Eskimos in the CANHR study, mean percentages of EPA in erythrocytes were 2.45 ± 1.77 % and mean levels of DHA were 6.44 ± 1.88 % (unpublished data).  In comparison, for men in the Carotene and Retinol Efficacy Trial, mean EPA and DHA contents of erythrocytes were 0.69 ± 0.327% and 2.78 ± 0.82%, respectively (A. Kristal, pers. comm.).  A typical Western diet includes < 0.2 grams per day of EPA and DHA, accounting for < 2% of energy intake  ADDIN EN.CITE (Kris-Etherton et al., 2000).  Based on twenty-four hour recalls, Yup’iks Eskimos consume 2-3 times more EPA and DHA than NHANES III (B. Luick, pers. comm.).  Also, Eskimos in the Norton Sound region of Northwest Alaska consumed between 1.7 to 6.9 grams per day of n-3 fatty acids (Nobmann et al., 2005).

From the above discussion, Yup’ik Eskimos consume more EPA and DHA than individuals who eat a Western diet.  However, there is a large range in the amount of EPA and DHA consumed and found in the erythrocytes of Yup’iks.  In erythrocytes, this range is from 0.19 to 9.62 % for EPA and 1.55 to 10.26 % for DHA (B. Luick, pers. comm.).  Age helps explain why there is such a large range of EPA and DHA observed in Yup’iks.  Bersamin et al.(2007) showed that individuals in the highest quintile of traditional food intake (> 32%) were approximately 20 years older than individuals in the lowest quintile of traditional food intake (< 13%).  Individuals in the highest quintile of traditional food intake had approximately 4% more PUFAs than those who were who ate the lowest amount of traditional foods.  The results of Bersamin et al. (2007) are supported by Nobmann et al.  ADDIN EN.CITE (2005), who showed that the amount of fats and PUFAs consumed is positively associated with age.  For example, men 17-39 years of age had 55.9 % of their energy from n-3 PUFAs.  In comparison, men 61-92 years of age had 64.0 % of their energy from n-3 PUFAs.
3.4 EFFECTS OF N-3 PUFAS IN THE HUMAN BODY
3.4.1 EFFECTS OF N-3 PUFAS ON CARDIOVASUCLAR DISEASE AND OBESITY
High levels of n-3 PUFAs such as EPA and DHA were associated with a low incidence of diabetes and coronary heart disease in Greenland Eskimos  ADDIN EN.CITE (Bang and Dyerberg, 1972; Bang et al., 1971).  Since then, possible mechanisms for why EPA and DHA contribute to reduced risk of disease have been examined.  Some of the proposed reasons for the protective effect of EPA and DHA are that they are antithrombotic and decrease platelet aggregation, decrease blood pressure, are antiarrythmic, decrease platelet sensitivity, decrease inflammation, and increase vascular endothelial function  ADDIN EN.CITE (Demaison and Moreau, 2002; Holub and Holub, 2004; Wijendran and Hayes, 2004).  In addition, n-3 PUFAs have been shown to contribute to increased thermogenesis, glucose clearance, and peroxisome FA oxidation.  PUFAs act to increase thermogenesis by regulating uncoupling protein 3.  PUFAs act to increase glucose clearance and peroxisome FA oxidation by inducing proteins involved with fatty acid oxidation and decreasing proteins involved with lipid synthesis.  n-3 PUFAs also decrease body fat deposition, adipogenesis, and adipose stores (Clarke, 2000).  Overall, consumption of n-3 PUFAs seems to favor a more catabolic state (Clarke, 2000).
3.4.2 EFFECTS OF LIPIDS ON CARDIOVASCULAR DISEASE, OBESITY, AND DIABETES
Low levels of plasma lipids were also a distinguishing factor between Greenland Eskimos and mainland Danes that consume a Western diet (Bang et al., 1971).  Possible mechanisms for why low levels of plasma lipids may be protective from chronic diseases have since been investigated.  In addition to favoring an environment that reduces inflammation, reduces platelet aggregation, and promotes a more catabolic state, n-3 PUFAs have been shown to decrease the level of serum triglycerides  ADDIN EN.CITE (Krebs et al., 2006).  Excess triglycerides in the serum are hypothesized to occur when tissues such as adipocytes, skeletal muscle, and the liver that normally store triglycerides and carbohydrates have reached their maximum capacity.  The resulting triglycerides and free fatty acids (FFAs) are subsequently deposited into tissues such as the pancreas or heart  ADDIN EN.CITE (Lelliott and Vidal-Puig, 2004).  Triglycerides deposited in the heart are associated with an increased risk of coronary heart disease, atherosclerosis, and stroke.  Increased storage of triglycerides in the heart causes increased heart rate, and increased risk of stroke, and heart attacks (McGavock et al., 2006).  The beneficial effect of n-3 PUFAs on cardiac disease may to be due to increased FA oxidation and therefore to a decreased amount of triglycerides available for synthesis, secretion, and storage  ADDIN EN.CITE (Wijendran and Hayes, 2004).  

Compared to other Native Americans, the occurrence of diabetes in Alaska Natives from 1990-1997 was low, approximately 3%.  Native Americans from the Atlantic region had the highest rate of diabetes at 17.4% (Naylor et al., 2003).  However among Native Americans since 1985, Alaska Natives have experienced the highest increase in diabetes cases.  This increase was 76%, while the lowest increase in diabetes among Native Americans was 16% for the Northern Plains (Naylor et al., 2003).  Recently, Alaska Natives have been found to have an amount of diabetes (8.1%) that is higher than that in the US population (7%) and comparable to non-Hispanic Caucasians (8.7%) (Naylor et al., 2003).  The increase of diabetes has been accompanied by an increase in the quantity of carbohydrates consumed, an increase in obesity, and an increase in the number of individuals with glucose intolerance (Naylor et al., 2003).  
3.5 Origin of PUFAs and LOCATION AND ROLE in HumanS
3.5.1 ORIGIN OF ESSENTIAL FATTY ACIDS
In humans, the n-3 and n-6 families PUFAs are primarily derived from dietary sources.  Humans cannot synthesize either alpha-linolenic acid or cis-linoleic acids, which are the parent compounds for n-3 and n-6 PUFAs, respectively.  These parent compounds are therefore referred to as essential fatty acids.  The essential fatty acid for n-6 PUFAs is cis-linoleic acid (LA, 18:2 n-6), which is found mainly in cereals, poultry, vegetable oils, breads, baked goods, and margarine.  The essential fatty acid for n-3 PUFAs is alpha-linolenic acid (ALA, 18:3 n-3), which is found mostly in canola, flaxseed, rapeseed oil, walnuts, and leafy green vegetables (Das, 2006).  Alpha-linolenic acid is also found in marine algae and phytoplankton (Wen and Chen, 2003).  
3.5.2 ORIGIN OF EPA AND DHA IN MARINE ENVIRONMENT
Although the essential fatty acids for both n-6 and n-3 are found in dietary sources mentioned above, humans cannot convert 18 carbon PUFAs such as the essential fatty acid alpha-linolenic acid into a 20 carbon PUFAs such as EPA(figure 3.4)  ADDIN EN.CITE (Davidson and Cantrill, 1985; Gerster, 1998; Simopoulos, 1999).  This inability is the result of an inefficiency of alpha-6 desaturase, which is the rate limiting step in converting 18 carbon PUFAs, such as ALA, to 20 carbon PUFAs, such as EPA  ADDIN EN.CITE (Davidson and Cantrill, 1985; Simopoulos, 1999).  It is estimated that only 15% of ALA is converted to EPA  ADDIN EN.CITE (Cao et al., 2006; Emken, 2003; Kris-Etherton et al., 2000).  However, there is retroconversion from DHA to EPA (Holub and Holub, 2004).  Additionally, ratios of FAs are important in converting ALA to EPA.  A ratio of LA to ALA of 4:1 or less is optimal for ALA to be elongated to EPA  ADDIN EN.CITE (Emken, 2003; Simopoulos, 1999). 

The overall result of human inefficiency in synthesizing EPA and DHA from ALA is that most EPA and DHA found in humans is obtained from dietary sources that can produce EPA and DHA (Gerster, 1998).  EPA and DHA originally are almost exclusively synthesized by primary producers, including the chloroplasts of marine algae and phytoplankton (Wen and Chen, 2003).  Algae, in addition to containing high levels of EPA and DHA, are a major source of nitrogen to consumers (Halbleib and Ludden, 2000).  The original source of most n-3 in fish is of eukaryotic origin due to the limited ability of fish to convert short chain PUFAs into long chain PUFAs  ADDIN EN.CITE (Barber, 2004; Uttaro, 2006).  Figure 3.3 is a simplified example of where humans obtain EPA and DHA.


Figure 3 3: Origin of EPA and DHA in the human diet.
Marine eukaryotes produce EPA and DHA which is consumed by higher trophic levels until the EPA and DHA are consumed by humans.


Figure 3 4: Overview of n-6 and n-3 metabolism.
The essential fatty acids, LA and ALA require Δ6-desaturase to convert an 18 carbon PUFA to a 20 carbon PUFA.  Humans have an inefficiency of Δ6-desaturase which causes the conversion of LA and ALA to arachodonic acid (AA) and eicosapentaenoic acid (EPA) to be inefficient.  Therefore, most of the EPA and DHA found in humans are derived from dietary sources.  In addition, EPA can be converted to DHA, and DHA can be retroconverted to EPA.  From Holub and Holub 2004. 

3.6 WHAT HAPPENS TO EPA AND DHA IN HUMAN BODY
Once ingested, n-3 PUFAs are incorporated into chylomicrons and move to the liver where elongation and desaturation occur.  Afterwards, the PUFAs are released into the bloodstream and incorporated into the membranes of many organs such as heart, lung, kidney, brain, skeletal muscle, and adipose tissue.  Once incorporated into a cell, two main events can occur.  One is that the PUFA can undergo oxidation in the mitochondria.  Otherwise, the PUFA will be incorporated into a complex lipid  ADDIN EN.CITE (Demaison and Moreau, 2002).  PUFAs such as EPA and DHA can be incorporated into is the sn2 position of phospholipid membranes.  Around 90% of EPA and DHA is taken up by phospholipid membranes  ADDIN EN.CITE (Croset and Lagarde, 1986; Rupp et al., 2004; von Shacky et al., 1985).  Triacylglycerols of EPA and DHA are absorbed more efficiently in the duodenum compared to ethyl esters  ADDIN EN.CITE (Rupp et al., 2004).  Individuals on a Western diet were given supplements of n-3 PUFAs.  The result of was that n-3 PUFAs are incorporated preferentially into phospholipid membranes at the expense of n-6 PUFAs .  This resulted in plasma and platelet membranes that were high in n-3 and low in n-6 PUFAs.  Additionally, n-3 PUFAs can also be incorporated into triglycerides and cholesterol esters  ADDIN EN.CITE (Rupp et al., 2004).

Once incorporated into phospholipids, n-3 and n-6 PUFAs can be converted to eicosanoids.  Eicosanoids are oxygenated derivatives of 20 carbon PUFAs and are involved in inflammation (figure 3.5).  Eicosanoids are divided into three different groups: the prostaglandins, thromboxanes, and leukotrienes.  Prostaglandins are involved in vasoconstriction, blood pressure, and inflammation.  Thromboxanes are involved in platelet aggregation and vasoconstriction while leukotrienes are involved in inflammation.  Arachidonic acid (AA), EPA, and to a lesser extent dihomo-γ-linoleic acid (DGLA), represent the beginning of different series of eicosanoids.  Eicosanoid series derived from AA are more inflammatory than those derived from EPA.  Overall, the benefits of EPA are that eicosanoids derived from EPA are less inflammatory than eicosanoids from AA.  A diet high in n-3 PUFAs will result in lower blood pressure, less vasoconstriction, and less platelet aggregation (Nelson and Cox, 2004).


Figure 3 5: Eicosanoid production.
Arachidonic acid is the beginning of the main pathway of eicosanoid production.  EPA represents the most important competing pathway to eicosanoids derived from arachidonic acid.  DGLA represents a third, less important, competing pathway to eicosanoids from arachidonic acid.  Arachidonic acid, EPA, and DGLA all result in different series of eicosanoids.  
From http://www.answers.com/topic/essential-fatty-acid-interactions (​http:​/​​/​www.answers.com​/​topic​/​essential-fatty-acid-interactions​)





Figure 3 6: Three ways EPA inhibits eicosanoids derived from AA (arachidonic acid).
The first way that EPA inhibits eicosanoids from being derived from AA is that EPA is incorporated preferentially into phospholipid membranes.  Secondly, EPA is released more readily from membranes because it competes with AA for phospholipase (PL).  Third, EPA competes with AA for access to PGHS (prostaglandin endoperoxide H synthases).  Together these three mechanisms allow more anti-inflammatory series 3 eicosanoids to be produced compared to the inflammatory series 2 eicosanoids from AA.

3.7 δ15N is aN APPROPRIATE biomarker for EPA and DHA AVAILABILITY
3.7.1 Dietary intake and biomarkers
Typically, food frequency questionnaires (FFQ) or 24 hour recalls (24HR) are used to assess the dietary intake of individuals in studies that examine the association between a disease and diet  ADDIN EN.CITE (Subar et al., 2003).  A precise measurement of a dietary component is necessary in order to relate diet to the risk of a disease (Wilkinson et al., 2007).  FFQs are administered by asking an individual the frequency and possibly the amount of food consumed over a specific period of time (usually months to a year).  This method has the advantage of being cheap and easy and does not affect a person’s eating habit.  However, FFQs have been found to underreport intake and have a low correlation with true intake  ADDIN EN.CITE (Kipnis et al., 2003; Subar et al., 2003) ADDIN EN.CITE .  Compared to multiday diet records or 24 hour recalls (24HR), FFQ have a correlation that is typically <0.4 and rarely > 0.6  ADDIN EN.CITE (Kristal et al., 2005). ADDIN EN.CITE   A major reason for this is that FFQs are dependent on a person’s memory  ADDIN EN.CITE (Brio et al., 2002).  In order to validate FFQs, the use of one or more 24HRs was suggested  ADDIN EN.CITE (Subar et al., 2003).

A 24HR is designed to estimate a person’s short-term intake.  This is done by interviewing the respondent.  The interviewer asks the respondent to detail what they have consumed in the last full day.  Advantages to a 24HR include its ease on both the interviewer and respondent.  Also, the respondent’s food intake is unaltered.  Negative aspects of a 24HR include reliance on the respondent’s memory and difficulty in estimating portion size.  Additionally, a person’s diet varies day by day and 24HR is therefore inappropriate for analysis of diet effects on disease  ADDIN EN.CITE (Brio et al., 2002).  An exception would be if multiple 24HRs were performed; however this requires considerable effort on the part of the interviewer and respondent.  Overall, 24HR, like FFQ, underestimate dietary intake  ADDIN EN.CITE (Subar et al., 2003).  

One way to accurately measure aspects of dietary intake is to use biomarkers, such as doubly-labeled water or nitrogen in urine  ADDIN EN.CITE (Kipnis et al., 2003).  A biomarker is a biological characteristic that can be objectively measured in order to evaluate biological processes.  Biomarkers can be used in the diagnosis of a disease, to determine the stage of a disease, to indicate the prognosis of a disease, and to predict and monitor response to an intervention  ADDIN EN.CITE (Atkinson et al., 2001; De Caterina and Massaro, 2005; Holub and Holub, 2004; Nelson and Cox, 2004).  Both doubly-labeled water and nitrogen in urine are used as reference methods to both 24HR and FFQs (Paul et al., 2005).  Biomarkers have the advantage of not being dependent on an individual’s memory and not disrupting their normal dietary patterns.  Negative aspects of biomarkers are their cost, invasiveness, and the fact that they are often nutrient specific (Cade et al., 2002).  Overall, biomarkers have been shown to be better estimators of habitual diet intake compared to other methods such as FFQs (Brio et al., 2002).  Since biomarkers are often nutrient specific, a good biomarker is one that is highly correlated to the nutrient under investigation.
3.7.2 What are stable isotopes and δ15N?
The biomarker for EPA and DHA intake is the stable isotope of nitrogen (δ15N). Stable isotopes are any element with differences in the number of neutrons that does not experience radioactive decay.  For example, nitrogen has two main isotopes, one with 14 neutrons and the other with 15.  One isotope is usually present at a lower amount compared to the other isotope.  For nitrogen, 0.366% is 15N while 99.633% of nitrogen is 14N (Hobson, 1999).  Delta (δ or d) is used to express the ratio of isotopes in parts per thousand (‰) which is often referred to as “per mil notation”(del Rio, 2005).  Delta is calculated as:

δX= [Rsample/Rstandard)-1] x 103 ,

where X represents an isotope, such as 15N, and R is the ratio of isotopes, such as 15N/14N.  For nitrogen, Rstandard is nitrogen gas in the atmosphere (Peterson and Fry, 1987).  Therefore, δ15N represents the relative proportion of 15N in a sample compared to nitrogen gas in the atmosphere.  The larger the value of 15N, the more 15N present in the sample compared to the standard.  Negative values of δ15N represent the presence of less 15N in the sample compared to the standard.
3.7.3 Relationship between diet and δ15N
Fractionation occurs when one isotope is preferentially used in a reaction.  This process is the result of differences in mass and bond strength of stable isotopes.  Heavier isotopes have stronger bonds and often react more slowly compared to the lighter isotope.  This causes heavier isotopes to become concentrated in substrates (del Rio, 2005).  For example, Minagawa and Wada (1984) showed that 15N became enriched with each increasing trophic level in a marine environment.  Generally, studies have found that with each increase of a trophic level 15N becomes enriched by 3-4 ‰ (Kelly, 2000).  Overall, as fractionation occurs with each higher trophic level, more of the heavy isotope accumulates.  This results in the value of delta, for example 15N, to increase as more of the heavy isotope is present in the sample.    

Marine environments typically have longer food chains compared to terrestrial and aquatic environments (Dunne et al., 2004).  Additionally, humans harvest species from the marine environment that are at high trophic levels (Dunne et al., 2004).  Additionally, the marine nitrogen cycle produces more enriched 15N compared to other ecosystems (Wilkinson et al., 2007).  Because humans harvest marine subsistence foods that are typically at a higher trophic level compared to foods harvested from other ecosystems, more fractionation has occurred in marine foods.  Therefore, humans that consume a diet rich in marine foods should have higher δ15N values than humans that consume a diet rich in terrestrial foods.  Consequently, values of δ15N should be able to differentiate between marine and terrestrial food sources.  This was recently shown by Wilkinson et al.  ADDIN EN.CITE (2007) who compared marine and terrestrial food sources and found that marine food sources such as halibut and salmon had higher δ15N signatures than terrestrial food sources such as beef, chicken, moose, and caribou (Figure 3.7).  


Figure 3 7: δ15N for various food sources.
For marine sources of food, such as halibut and salmon, δ15N is higher than for other sources of food.  From Wilkinson et al. 2007.
 






Figure 3 8: δ15N correlated with EPA and DHA in erythrocyte membranes.
From O’Brien et al. submitted. 

3.7.4 Relationship between diet and EPA and DHA




Figure 3 9: Effects of fish oil supplementation on erythrocyte membrane n-3 PUFAs.




Figure 3 10: Increase of EPA and DHA in erythrocyte membranes.
With fish oil supplementation, levels of EPA and DHA increased in erythrocyte membranes.  From Cao et al. 2006.

Additional studies have expanded on the idea that levels of EPA and DHA increase in response to increased amounts of dietary EPA and DHA.  These studies have shown that DHA in erythrocytes is a good marker for marine n-3 fatty acid intake  ADDIN EN.CITE (Poppitt et al., 2005; Sun et al., 2007).  In a study by Poppitt et al.  ADDIN EN.CITE (2005) volunteers were given diets high in saturated fatty acids and high in unsaturated fatty acids for three weeks with a four week washout period between diets.  They concluded that irrespective of the dietary treatment, DHA showed the strongest correlation with erythrocyte levels.  This correlation ranged from Pearson correlations between r=0.373 and r=0.491 depending on the diet and day of observation.  Sun et al.  ADDIN EN.CITE (2007) examined the ability of over 30 fatty acids in plasma and erythrocytes to reflect long-term fatty acid intake from validated FFQs.  FFQs were validated with multiple-week diet records and biomarkers in adipose tissue.  They found that DHA, particularly in erythrocytes, correlated most strongly with validated FFQ (Spearmen r=0.56).  EPA also had moderate correlation with FFQ (Spearmen r=0.38) in erythrocytes.  Both Poppitt et al. (2005) and Sun et al. (2007) support that DHA can be used as a biomarker for intake of marine derived n-3 fatty acids.

3.7.5 δ15N IS A BIOMARKER FOR EPA AND DHA AVAILABILITY






Chapter 4 DETERMINING IF THERE ARE INTERACTIONS BETWEEN ADIPOQ, PPARG, AND PPARGC1A AND δ15N.
MATERIALS AND METHODS
4.1. DATA COLLECTED PREVIOUSLY BY CANHR RESEARCHERS
A total of 10 communities participated in CANHR from December 2003 to March 2006.  Individuals who were non-pregnant and 14 or older at the time of recruitment were encouraged to participate.  All protocols described in this section were approved by the University of Alaska Institutional Review Board, the National Area Indian Health Service Institutional Review Board, and the Yukon Kuskokwim Human Studies Committee (Boyer et al., 2007b)
4.1.1. ANTHROPOMETRIC AND BLOOD CHEMISTRY DATA
A total of seven obesity related phenotypes were included in this study that were collected between December 2003 and March 2006.  These phenotypes were body mass index (BMI), percent body fat (PBF), waist circumference (WC), sum of skin-folds (SSF), plasma adiponectin levels (adiponectin), plasma triglyceride levels (TG), and HDL cholesterol levels (HDL).  The variable SSF represents the sum of four skin-fold measurements: thigh, triceps, subscapular, and abdominal.  

Anthropometric measurements are represented by BMI, PBF, WC, and SSF.  These were obtained by trained observers who used established protocols from NHANES III Anthropometric Procedures Manual (Lohman et al., 1988)  These measurements included height, weight, 4 circumferences (triceps, waist, hip, and thigh), and 4 skin-folds (tricep, subscapular, abdominal, and thigh).  BMI was calculated by taking weight in kilograms and dividing by height in meters squared.  WC was measured with a Gulick II 150 cm tape (Country Technologies, Inc, Gays Mills WI).  WC was measured directly below the lowest lateral portion of the rib case (Boyer et al., 2007b).  PBF was measured from electrical bioimpedance using a Tanita TBF-300A body fat analyzer (Tanita Corp, Arlington Heights, IL) (Boyer et al., 2007b).  Weight was also measured with the Tanita TBF-300A.  Blood chemistry is represented by adiponectin, HDL cholesterol, and plasma triglycerides.  Adiponectin was assayed with a radiommunoassay kit using I125-iodinated murine adiponectin tracer, a multi-species adiponectin rabbit anti-serum, and human adiponectin standards from Linco Research.  HDL and TG were measured with a Poly-Chem System Chemistry Analyzer (Polymedco Inc, Courland Manor, NY) (Boyer et al., 2007b).
4.1.2 RED BLOOD CELL COLLECTION AND DNA ISOLATION
Venous whole blood from each participant was collected in EDTA tubes.  Some of this blood was then stored for further use. DNA was isolated from the buffy coat of venous whole blood using the Puregene kit (Gentra Systems, Minneapolis, MN).
4.1.3 COLLECTION OF δ15N FROM RED BLOOD CELLS
A biomarker for EPA and DHA intake, δ15N, has been validated previously by researchers in CANHR  ADDIN EN.CITE (O'Brien et al., submitted; Wilkinson et al., 2007).  Values for δ15N were obtained using the following procedure.  Venous whole blood was collected in untreated glass tubes and centrifuged for 15 minutes at 1000 rpm.  The remaining whole red blood cells were then stored at -80°C until analysis.  To obtain δ15N values for each individual, 250 µl of packed RBCs from venous whole blood collected in EDTA tubes were placed in an autoclave safe tube.  The samples were then sterilized with an autoclave at 121° C for 20 minutes.  Between 0.7-0.8 mg of sample was placed in 3.75 x 3.5 mm tin capsules and dried at 50-60° C for 1-2 days.  Dried blood samples were approximately 0.3 mg.  Blood samples were then analyzed for nitrogen isotope ratios at the Alaska Stable Isotope Facility, using continuous-flow isotope ratio mass spectrometry.  A Costech ECS4010 Elemental Analyzer (Costech Scientific Inc.) combusted samples to N2 gas, which was carried in a constant flow of helium to a Finnigan Delta Plus XP isotope ratio mass spectrometer via the Conflo III interface (Thermo-Finnigan Inc.).  Gas was ionized and separated by magnetic field (e.g. 14N2 and 14N15N), and measured using Faraday cup collectors.  The standard used for nitrogen was Air N.  Multiple peptone standards of between 0.25-0.3 mg were concurrently weighed and run to assess analytical precision.

4.1.4 PEDIGREE CONSTRUCTION
Complete data was collected for 987 participants between December 2003 and March 2006.  Several questions were asked in order to determine each participant’s biological relatives.  This information was then stored in the program Progeny (Progeny Software LLC, South Bend) (Boyer, pers. comm.).  The program PedMerge (Wang et al., 2005) and was used to create a pedigree file that determined the relationships between participants from the 10 communities that participated (Boyer, pers. comm.).  The output from PedMerge contained 1807 individuals, 987 were participants.  There were a total of 45 pedigrees that were determined using PedMerge that ranged in size from 1412 to 3 individuals.  
4.2 DATA COLLECTED SPECIFFICALLY FOR THIS STUDY
4.2.1 CANDIDATE GENE SELECTION
Three main criteria were used in order to select candidate genes.  The first was that the gene resides in a region of the genome that had previously been implicated in ≥3 genome wide scans with obesity phenotypes.  The second was that the gene be a part of the adiponectin pathway.  The third was that the gene be associated or influenced with omega-3 PUFAs.  
4.2.2 SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SELECTION
Two main criteria were used to select SNPs for genotyping in each candidate gene.  The first was that the SNP tag as many other SNPs as possible using data from HapMap (The International HapMap Consortium, 2005), and the program Haploview (Barrett et al., 2005).  The second was that the SNP be previously reported to be associated with an obesity or T2D phenotype.  A third method of SNP selection was used only for ADIPOQ.  Previously, researchers in CANHR re-sequenced the ADIPOQ gene in 30 unrelated Yup’ik Eskimos at the extremes of adiposity. This re-sequencing included all exons, intron-exon boundaries, and promoter region. Sequencing was performed by Agencourt (Agencout Bioscience Corporation, Beverly MA) and was conducted in duplicate on both strands of DNA. Two additional SNPs, SNP1T>G (rs17846866) and SNP2T>G (no rs number) located on chromosome 3 at 188053521, were identified.  To the best of our knowledge, SNP2T>G has only been identified in Yup’iks (Boyer pers. comm.).  
4.2.3 SNP GENPTYONG ASSAY
Selected SNPs were genotyped using the ABI TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA).  SNPs were genotyped according to the manufacturer’s directions.  10 ng of DNA was placed in each well of a MicroAmp optical 384-well reaction plate with barcode.  Also in each plate there were two negative controls (blanks) and four positive controls.  The DNA was allowed to dry in a covered location for 2-3 days.  To each well, 2.5 μl of TaqMan universal PCR master mix, 0.25 μl of 20X assay mix, and 2.25 μl of water were added for a total volume of 5 μl.  The plate was then covered with MicroAmp optical adhesive film and placed in an ABI 7900HT Real Time PCR.  Amplification of DNA was done with reaction conditions of 2 minutes at 50º C, a hold of 10 minutes at 95º C, 40 cycles of denature and anneal/extension of 15 seconds at 92º C, and 60 seconds at 60º C.  For ADIPOQ SNP2 the number of cycles was raised to 50.  Allelic discrimination was performed with ABI S.D.S 2.2.2 software.  Positive and negative controls were examined manually to ensure proper discrimination.


4.3 DATA ANALYSIS PROCEDURES FOR THIS STUDY
4.3.1 DESCRIPTIVE ANALYSIS
Descriptive analysis was performed to determine the mean and standard deviation of each untransformed phenotype and for δ15N.  Additionally, descriptive analysis was used to determine the allele frequency for each SNP.  One-way ANOVA was performed to determine whether each phenotype differed between men and women.  All descriptive analysis was done using SPSS (SPSS INC, Chicago IL).  
4.3.2 POPulation GENETIC STATISTICS
Three methods were used to check HWE for each SNP.  The first was to use the formula presented by B.Weir (Weir, 1996).  The second was to use the program Haploview (Barrett et al., 2005) and the third was to use the program SOLAR (Almasy and Blangero, 1998).  In addition to testing HWE, the program SOLAR (Almasy and Blangero, 1998) was used to test for Mendelian errors and the amount of LD between SNPs.
4.3.3 PedCut to create subpedigrees
Before proceeding with the mixed model analysis, the pedigrees in CANHR needed to be simplified into smaller sub-pedigrees.  This was mainly because the CANHR dataset consisted of large pedigrees with one pedigree consisting of more than 700 participants and over 700 non-participants.  The program selected to create sub-pedigrees was PedCut  ADDIN EN.CITE (Liu et al., 2008).  PedCut is an automatic pedigree splitting algorithm based on user-specified maximum bit-size.  The algorithm also relies on the user identifying subjects of interest (SOI).  SOI are similar to the idea of a core individual.  SOI are individuals that have phenotypic and genotypic information.  All resulting sub-pedigrees will have a bit-size that is equal to or less than the original bit-size.  Generally, PedCut assumes that some SOI share a genetic variant that is IBD and contributes to their phenotype.  Therefore, the aim of PedCut is to create sub-pedigrees that contain a maximum number of SOI who are related to a common ancestor (ie IBD) (Liu et al., 2008).  

PedCut works by first determining the kinship coefficient between any two relatives in the pedigree.  The kinship coefficient is a measure of how related two individuals are.  The basis of the kinship coefficient is the probability that two randomly selected alleles from a pair of individuals are IBD.  Values for the kinship coefficient range from 1 to 0.  For example, a pair of individuals with a kinship coefficient of 1 would be monozygotic twins while a pair of individuals with a kinship coefficient of 0.5 would be siblings.  After kinship coefficients are determined, there are three basic steps to the algorithm implemented in PedCut.  The first step results in a matrix of subgroups that are sorted based on kinship.  The second step links the maximum number of SOI to a common ancestor. Sub-pedigrees are removed from further evaluation if they have the largest number of SOI.  The third step removes the SOI present in the sub-pedigree identified in step two and then moves to step one until all SOI are placed in a sub-pedigree.  By default, all second cousin or closer relationships are maintained between SOI (Liu et al., 2008).

A pedigree breaking program, PedCut (Liu et al., 2008), was used to trim the pedigrees created from PedMerge (Wang et al., 2005).  The input file for PedCut was in pre-makeped linkage format and a bit size of 30 was used.  Individuals who had phenotype and genotype information available were designated as a SOI.  
4.3.4 Mixed model to perform association and GEI studies
CANHR is based on a cross-sectional community based participatory research (CBPR) design.  Using this approach, individuals in each participating community were encouraged to participate but were not chosen based on any prior criteria such as disease status.  Information about each participant’s nuclear family was collected (Boyer, pers. com).  At the time of this study, 1807 individuals were distributed in 45 pedigrees that ranged in size of 1412 to 3 individuals.  Of the 1807 individuals, 987 of these were participants in CANHR.  Each pedigree included participants and non-participants.  

Main effects association studies, as well as association studies that include GEIs, can use both unrelated and related individuals.  Related individuals are correlated because they share genetic and often shared environmental factors.  An advantage of using multiplex families in association studies is that affected individuals who have affected relatives have a higher expected frequency of alleles that increase susceptibility for a genetic trait than affected individuals who do not have affected relatives.  As a result, the power to detect an association is expected to increase when affected individuals with affected relatives are included in the study (Roeder, 2005).  However, when related individuals are included in an association study, one must account for the fact that subjects who are biologically related have correlated genotypes. A methodology that takes advantage of relatedness among individuals in our study is employed.  This methodology will be described in the upcoming sections.

There are several methods that can model family data in association testing with continuous trait outcomes such as a mixed linear models (MLM) (Yu et al., 2006), family based association testing (FBAT) that tests both linkage and association (Lake and Laird, 2003), a likelihood based method in ASSOC (George and Elston, 1987), and adjustment for family relationship using variance components in SOLAR (Almasy and Blangero, 1998).  MLMs were chosen for association modeling in this study since they are widely used, powerful, and easy to implement using standard software such as SAS (Cary, NC).  Methods that can use information from the entire pedigree in an analysis will have more power to detect an association compared to methods that break a pedigree (Yu et al., 2006).  However, some pedigrees in this study were very large N>100 and pedigree breaking was necessary to avoid modeling distant relatives with negligible correlations in MLMs.  

Any arbitrary restriction on the size or shape of a pedigree results in the loss of information from that pedigree (Lange and Sinsheimer, 2004).  Additionally, breaking any close relationship within a pedigree increases the chance of finding a false positive and decreases the power of the study (Liu et al., 2008).  In many pedigrees, such as the pedigrees in the CANHR study, there are individuals who have phenotypic and genotypic information and those who do not.  Individuals with phenotypic and genotypic information are commonly referred to as core members.  The simplest method of creating sub-pedigrees would be to delete all individuals who do not have phenotypic or genotypic information.  However, this risks obscuring the relationships between members of the core members (Lange and Sinsheimer, 2004).  Therefore, the ultimate goal in the use of pedigrees in association analysis is to find a minimal set of individuals, that includes core members, that permits the deduction of the correct relationships among members of the core. For our analysis we carefully chose a pedigree cutting method to maximize information obtained from family relationship with respect to genetic association. Mixed models are discussed in detail below.  

Mixed model analysis is based on linear regression.  The basic idea behind linear regression is to predict an independent variable based on one or more dependent variables.  The basic linear regression model with one dependent variable has the form:

Yi = βo + β1Xi + εi

where Yi represents the dependent variable, βo and β1 are parameters, Xi is the independent variable, and εi is random error.

Mixed models are similar to linear regression but also have the ability to accommodate random effects.  The basic idea of mixed models is to fit a linear model with the independent variable modeled directly by linear combinations of fixed and random effects.  Fixed variables are those where it is assumed that all possible levels are represented in a population.  For example, since we assumed that only two alleles are present at each SNP location, each SNP was considered a fixed variable.  Similarly, sex is a fixed variable because we assume there are only two sexes in the entire population.  Random variables are assumed to represent a sample of all potential levels in a population.  For example, pedigree number was treated as a random variable.  The main difference between the two models is in relation to fixed and random effects.  Linear regression only accommodates fixed effects while a mixed model accommodates both fixed and random effects.  The general mixed model has the form:

Yi = Xiβ + Ziγi + εi

Where Yi is a vector that contains the dependent observations, Xi is a matrix that relates the independent observations to fixed effects, β is a vector of unknown fixed effects, Zi is a matrix that relates the observations to random effects, γi is a parameter vector corresponding to unknown random effects, and εi is a vector of residuals.  

For the association analysis presented here, the fixed variable is the SNP under investigation and the random variable is the family ID.  Therefore, the mixed model for the association study here takes the general form of:

Yi = SNPβi+ FamIDγi + εi

Where Y represents the phenotypic variable of interest such as BMI, β1 represents the fixed effect of the SNP under investigation, γi represents the random effect of the due to familial effect, and FamID represents the pedigree number an individual is part of, and ε represents non-shared random effects.  It has been shown that this approach is superior to within cluster re-sampling (WCR) where the mixed model approach we describe gives valid type I error rates in simulation testing but WCR does not (Chung et al., in review; Sokal and Rohlf, 1969).

The statistical method chosen for the analysis is based on linear regression.  Because of this, each phenotype was checked for normality using the Box-Cox procedure (Box and Cox, 1964).  Appropriate power transformations were implemented to ensure each phenotype had a normal distribution.  Transformed obesity related phenotypes were used throughout the analysis.  Table 1 shows the transformations used for each phenotype.

Table 4 1: Transformation of the phenotypes in the study











The resulting output files from PedCut were merged in, SPSS (SPSS Inc., Chicago IL) to a file that contained relevant phenotypic and genotypic information.  SNP genotypes were coded as 0, 1, and 2.  A code of 0 represented homozygotes for the major allele, 1 represented heterozygotes, and 2 represented homozygotes for the minor allele.  This file was then converted to an Excel file and imported into, SAS (SAS Institute Inc, Cary NC).  In SAS, mixed model analysis was done using PROC MIXED.  In PROC MIXED, three statements were used; class, model, and random.  Gender, the SNP under investigation, and the pedigree number from PedCut were included in the class statement.  In the model statement, each phenotype under investigation was considered the dependent variable and fixed effect covariates were gender, age, age squared, and 15N.  The SNP was modeled as a fixed effect.  For models that included GEIs, an interaction term was included to model the interaction between the SNP and δ15N.  The random statement had the pedigree number.  
4.3.5 DETERMINATION OF SIGNIFICANT RESULTS AND CONTROL FOR MULTIPLE TESTING






The means for each phenotype and δ15N are shown in Table 4.2.  BMI, PBF, HDL, and SSF differed between the genders.  The δ15N biomarker for EPA and DHA intake also differed between genders.  Overall, Yup’ik females had more body fat, higher HDL cholesterol levels, and had higher intake of marine subsistence foods when compared to males.

4.5 ALLELE FREQUENCEIS AND POPULATION GENETIC STATISTICS
Results of population genetic statistics are presented in tables 3 through 5.  The genotype frequencies for each SNP investigated are presented in table 4.6.  Frequencies for the minor allele ranged from 45% to less than 1%.  Only 2 SNPs had minor allele frequencies (MAFs) of less than 1% (ADIPOQ rs1730059 and PPARA rs1800206).  







Table 4 2: Demographics for individuals in the CANHR study by gender1.

Phenotype	All	Female	Male	P
age (y)	38.10 ± 17.322 (978)	38.60 ± 17.25 (528)	37.53 ± 17.4 (450)	0.3383
BMI (kg/m2)	27.69 ± 6.09 (966)	29.12 ± 6.71 (522)	26.01 ± 4.75 (444)	0
Percent Body Fat  (%)	29.14 ± 10.96 (966)	35.75 ± 8.67 (522)	21.37 ± 7.83 (444)	0
Waist Circumference  (cm)	90.47 ± 14.96 (969)	91.29 ± 15.81 (524)	89.51 ± 13.84 (445)	0.064
Adiponectin (µg/mL)	9.95 ± 5.45 (977)	10.35 ± 5.81 (528)	9.49 ± 4.96 (449)	0.014
Triglyceride (mg/dL)	85.26 ± 48.03 (978)	84.65 ± 44.1 (528)	85.97 ± 52.32 (450)	0.668
HDL (mg/dL)	60.63 ± 17.8 (979)	64.32 ± 18.57 (528)	56.32 ± 15.82 (450)	0
Sum of Skinfolds  (mm)	91.28 ± 46.24 (952)	117.03 ± 39.17 (519)	60.41 ± 33.41 (433)	0
δ15N (‰)	8.98 ± 1.52 (957)	9.12 ± 1.51 (522)	8.81 ± 1.52 (435)	0.002

1 n in parentheses




Table 4 3: HWE calculations.
HWE was calculated using three difference methods.  These were the program SOLAR, the program Haploview, and an excel sheet using the formula for HWE in Weir 1996.  All p values of 0.05 or less represent a rejection of HWE and are highlighted. 

















Table 4 4: Mendelian errors.



















Table 4 5: Linkage disequilibrium between SNPs in study.
Amount of linkage disequilibrium for SNPs included in association analysis.  Significant linkage disequilibrium is present between
PPARG rs1801282 and PPARG rs3856806 (0.921865).  Also, there is high linkage disequilibrium between PPARG rs10865710 and 
PPARG rs1801282 (0.725051).  However the amount of linkage disequilibrium between these two SNPs is not enough to qualify them as
tag SNPs.  Therefore, the only SNPs that tag each other in this analysis are PPARG rs1801282 and PPARG rs3856806 which are 
highlighted.  The amount of linkage disequilibrium between all other pairs of SNPs does not suggest any SNP is a tag SNP of another 
SNP in analysis.


































The resulting PedCut output file contained 1586 individuals in 120 sub-pedigrees that ranged in size of 36 to 3 individuals.  A total of 870 SOIs were included in the pedigrees.  However, 25 of these individuals were included in 2 or more pedigrees.  Therefore, 845 individuals were included in one or more pedigrees.  There were 136 SOI that were not included in a pedigree, but were included in the analysis as singletons.  In summary, a total of 981 individuals were included in the association and GEI analysis.

4.7 ASSOCIATON
Association results for the main effects between each SNP and phenotype are shown in table 4.7.  Each p-value has been corrected for gender, age, age squared, δ15N, and pedigree number.  Two associations remained significant after correction for multiple testing.  ADIPOQ SNPs rs17846866 (SNP 1) and SNP 2 are associated with increased plasma adiponectin (p=0.0001 and p=0.0001 respectively).  Additional associations that were significant at a p ≤0.05 before correction for multiple testing included: ADIPOQ rs1730059 (G) with decreased SSF and increased HDL, PPARG rs12497191 (A) with decreased TG, PPARG rs10865710 (C) with decreased BMI and PBF.

4.8 GENE BY ENVIRONMENT





Table 4 7: Association results: main effects.  
Column abbreviations include: body mass index (BMI), percent body fat (BF), waist circumference (WC), sum 
of skin-folds (SSF), plasma adiponectin (adiponectin), plasma triglcyerides (TG), and HDL cholesterol (HDL). 
Numbers in each column correspond to the p-value of that phenotype with the genotype in the same row.  
All p-values of less than or equal to 0.1 are highlighted in bold.  Associations for main effects that are 
















Table 4 8: Gene by Environment Interactions.
Column abbreviations include: body mass index (BMI), percent body fat (BF), waist circumference (WC), 
sum of skin-folds (SSF), plasma adiponectin (adiponectin), plasma triglycerides (TG), and 
HDL cholesterol (HDL).  Numbers in each column correspond to the p-value of that phenotype with
the interaction between the genotype and δ15N in the same row.  All p-values of less than or equal to


















Table 4.9 shows the direction for each main effect (assocaiton) and GEI in ADIPOQ.  For the ADIPOQ SNP rs17300539 (-11391), located well upstream of the transcription start site, a copy of the major allele G is associated with increased HDL cholesterol levels and decreased BMI and sum of skin-folds in Yup’iks.  Previous studies have not reported these associations, but they have demonstrated that the A allele is associated with higher adiponectin levels, which was not replicated in our study population (Heid et al., 2006).  Additionally, the A allele has previously been associated with a 2.5-fold increase in the transcriptional activity of ADIPOQ (Bouatia-Naji et al., 2006).  

Many studies have shown a positive association between HDL cholesterol and plasma adiponectin  ADDIN EN.CITE (Mantzoros et al., 2005; Zietz et al., 2003).  Since HDL and adiponectin are positively correlated and the A allele has previously been associated with higher plasma adiponectin levels, one might expect the A allele to be associated with increased HDL cholesterol levels.  Instead this study observed increased HDL cholesterol levels for the opposite allele, G.  The amount of adiposity may be one reason the association between the A allele and HDL cholesterol levels is different between that observed and what would be expected.  Kantartzis et al.  ADDIN EN.CITE (2006) showed that as the amount of adiposity increased with the strength of the association between plasma adiponectin and HDL cholesterol.  Additionally, the mechanism linking adiponectin levels and HDL cholesterol remains unclear.  Schneider et al. (2005) showed that there may be a direct or indirect relationship between plasma adiponectin and hepatic lipase activity by an unknown mechanism.  They suggested one mechanism that may link the two may be mediated by PPARG.  

Figure 4.2 shows that at a p-value of 0.1, there was a GEI between ADIPOQ SNP rs17300539 (-11391) and triglycerides.  For individuals with a genotype of GG, triglycerides increase when consumption of EPA and DHA is high (δ15N above the mean).  Thus, this model shows increased susceptibility for triglyceride increase for individuals with a genotype of GG with more intake of EPA and DHA.

Table 4 9: Direction of association and GEI results for ADIPOQ
Associations that were significant at a p-value of 0.1 or less prior to Bonferroni are presented.  The column labeled, “p-value,” represents the overall significance of the SNP in the mixed model.  The column labeled, “β (standard error),” represents the β coefficient which indicates the direction of the association along with the standard error.  Finally, the column labeled, “β p-value,” represents the p-value of the β coefficient. Values with a * indicate the association is significant after Bonferroni correction.

 	Phenotype	Genotype	Model p-value	β (standard error)	β p-value
 	 	 	 	 	 














Figure 4 1: Interaction plot for ADIPOQ rs17300539 (-11391) and δ15N on plasma triglycerides
The y-axis is plasma adiponectin that has been transformed.  The x-axis represents either a low (0) or high (1) value of δ15N.  Low and high δ15N was determined by finding the mean of δ15N.  High δ15N was any value greater than the mean δ15N, and low δ15N was any value equal to or less than the mean δ15N.  Genotypes are described by the box on the right of the interaction plot.

For SNP 1 (rs17846866) and SNP 2 (no rs number assigned), a copy of the major allele, A and T respectively, is associated with increased plasma adiponectin.  Both of these SNPs were identified in re-sequencing of 30 unrelated Yup’ik Eskimos in our study population.  Additionally, SNP 2 is located 12 base pairs upstream of exon 2, and SNP 1 is located 81 base pairs upstream of SNP 2.  However, even though these SNPs are only separated by 81 base pairs, they are not in LD with one another or with -11391.  Since both SNPs are associated with adiponectin and are not in LD with one another it is likely they both independently influence adiponectin levels or are in LD with variants that influence adiponectin levels.  Since we only re-sequenced the intron-exon boundaries of the adiponectin gene in Yup’iks, it is possible that another unidentified common SNP is present in the region. Overall, SNPs 1 and 2 have not previously been studied and our results suggest that the major alleles of these SNPs are associated with increased plasma adiponectin levels.

4.10 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG)
Table 4.10 shows the direction of associations that were significant at p ≤ 0.05 before correction for multiple testing.  For rs10865710 (C-681G), a copy of the major allele (C) was found to be associated with decreased BMI, percent body fat, waist circumference, sum of skin-folds and plasma triglycerides.  Previously, the G allele was found to be associated with increased LDL levels and increased height  ADDIN EN.CITE (Meirhaeghe et al., 2003).  Additional investigators have examined the association of this SNP with obesity phenotypes in children.  These studies found that when C-681G was examined alone, there was no association between this SNP and obesity phenotypes.  However when C-681G was examined with other SNPs, like with P12A and C1431T (H447H), the G allele was associated with accelerated growth (Cecil et al., 2005).  Another study that looked at C-681G in a haplotype with 8 other SNPs found the C allele of C-681G was associated with decreased glucose levels  ADDIN EN.CITE (Wei et al., 2006).  

In the original paper that described C-681G, Meirhaegehe et al. (2003) found that this polymorphism is located in a STAT5B binding site  ADDIN EN.CITE (Meirhaeghe et al., 2003).  STAT5, the signal transducer and activator of transcription factor 5, is a mediator of adipogenesis and is involved in regulating the expression of PPARG  ADDIN EN.CITE (Nanbu-Wakao et al., 2002).  Cross-talk between PPAR and STAT5 is known, with each being able to regulate the expression of the other.  The expression of either PPAR or STAT5 is dependent on environmental factors such as the concentrations of PPAR agonists and growth hormones  ADDIN EN.CITE (Shipley and Waxman, 2004).  Based on this knowledge, it seems that polymorphisms in PPARG that affect the binding of STAT5B, such as C-681G, may affect the ability of these two transcription factors to respond to each other based on environmental input.

Overall, there have been few studies that have examined the role of C-681G on obesity phenotypes.  The results of this study show newly described associations of C-681G with BMI, body fat, waist circumference, sum of skin-folds, and plasma triglycerides.  





Table 4 10: Direction of associations in PPARG
Associations that were significant prior to Bonferroni are presented.  The column labeled, “p-value” represents the overall significance of the SNP in the mixed model.  The column labeled “B (standard error)” represents the B coefficient which indicates the direction of the association along with the standard error.  Finally, the column labeled “B p-value” represents the p-value of the B coefficient. Values with a * indicate the association is significant after Bonferroni correction.
























Table 4 11: Direction of GEIs in PPARG
Associations that were significant prior to Bonferroni are presented.  The column labeled “p-value” represents the overall significance of the SNP in the mixed model.  The column labeled “B (standard error)” represents the B coefficient which indicates the direction of the association along with the standard error.  Finally, the column labeled “B p-value” represents the p-value of the B coefficient. Values with a * indicate the association is significant after Bonferroni correction.









Table 14.11 shows the direction of GEIs that were significant at p ≤ 0.1 before correction for multiple testing.  In addition to the associations we observed between rs10865710 and rs12497191 in PPARG, we observed that δ15N levels modify the association between two additional SNPs in PPARG, H447H and Pro12Ala and plasma adiponectin levels.  Figure 4.3 shows that δ15N levels modify the association between the PPARG Pro12Ala SNP and plasma adiponectin levels.  Additionally, we observed an association between P12A and plasma adiponectin at a p-value of 0.1.  The G (Ala) allele is associated with higher adiponectin levels when δ15N levels are low; however, when δ15N levels are high, and consequent consumption of omega-3 PUFAs is likely to be high, one or two copies of the C allele results in higher plasma adiponectin levels compared to the GG genotype.  Also, table 4.12 also shows that although not statistically significant, individuals with a copy of the major allele C (Pro) who consume more marine subsistence have improved phenotypes.  Similar to our observations with the PPARG H447H allele, consumption of high levels of marine foods where subsequent omega-3 PUFA levels are likely to be high may prove beneficial to most individual’s health.  This is because the C allele (Pro) is the more common allele in Yup’ik Eskimos, and individuals with a copy of the C allele who consume higher amounts of omega-3 PUFAs have higher plasma adiponectin levels.  In terms of the participants in this study, only about 7 % would be negatively affected in terms of lower plasma adiponectin levels by high consumption of omega-3 PUFAs.  

Table 4 12: Phenotypes by P12A genotype and δ15N
The mean for each of the seven phenotypes investigated was determined based on P12A genotype and δ15N.  Low and high δ15N were determined by finding the mean of δ15N.  High δ15N was any value greater than the mean δ15N, and low δ15N was any value equal to or less than the mean δ15N.  The row labeled N is the number of individuals with a specific genotype, CC, CG, or GG.  Numbers in parentheses represent the standard deviation from the mean value.

rs1801281 (P12A C>G)	Low δ15N	High δ15N	Low δ15N	High δ15N	Low δ15N	High δ15N
 	CC	CC	CG	CG	GG	GG
N	292	209	208	166	43	27
BMI	26.5 (5.6)	28.9 (6)	27.1 (6.6)	28.7 (6.1)	27.8 (5)	28.8 (6.6)
BF	26.7 (10.8)	31.9 (10.1)	26.9 (11.4)	32.1 (10.6)	29.3 (10.2)	31.7 (9.9)
WC	86.9 (13.7)	94 (14.2)	88.9 (16.1)	93.2 (14.9)	90.6 (14.2)	94.5 (16.9)
Adiponectin	9.5 (5.2)	10.6 (5.6)	9.3 (5.1)	11 (6.1)	9.8 (6)	8.3 (4.1)
TG	91.6 (65.3)	83.4 (41.9)	85.5 (37.5)	77.7 (35.1)	84.6 (34.3)	83.4 (33.2)
HDL	55.7 (15.1)	66.4 (19.6)	56.1 (15.7)	66.9 (17.9)	57.6 (18.5)	66.7 (17.1)






Figure 4 2: Interaction plot for P12A and δ15N on plasma adiponectin




Numerous studies have examined whether P12A is associated with obesity phenotypes such as BMI and insulin. The results of these studies were generally mixed, with some studies showing an association and others showing no association.  The first study to examine the effect of an environmental factor, the ratio of PUFAs to saturated fatty acids (P:S ratio), on the association of P12A with obesity phenotypes was conducted by Luan et al. ADDIN EN.CITE (2001).  They found that a high P:S ratio in individuals with the genotype Pro/Pro (C/C) was associated with a higher BMI.  Additionally, they found that when the P:S ratio was low individuals with the genotype Ala/X (G/X) also had a higher BMI.  Overall, they concluded that without the inclusion of environmental data it is difficult to examine the effect of a common polymorphism.  They suggested that this may be why association studies that did not include environmental data yielded in such heterogeneous results.

Not all studies that have included environmental data to examine the relationship between P12A and obesity have reached the same conclusion as Luan et al. (2001).  One study by Robitaille et al. (2003) found that individuals who consumed a high amount of total fat, or saturated fat, and who had the Pro/Pro genotype had a larger waist circumference, a higher BMI, and lower HDL.  Robitaille et al. (2003) concluded that the genotype Pro/Pro confers susceptibility to the diet and that Ala is protective.  They concluded that their results were opposite those of Luan et al. (2001).  Robitaille et al. (2003) showed that BMI varies with nutritional intake among individuals with at least one copy of the Ala variant. 

Other studies since those by Luan et al. (2001) and Robitaille et al. (2003) have examined the effect of fat intake on the association between P12A and obesity.  A study by Memisogle et al.  ADDIN EN.CITE (2003) found that when total fat intake was high, individuals who were Pro/Pro had a higher BMI.  They also examined the effect of monosaturated fats and observed that when monosaturated fat intake was high, individuals who where Pro/Ala or Ala/Ala had an inverse relationship with BMI.  The results of Memisogle et al. (2003) appear to agree with those from Robitaille et al. (2003).  Both studies showed that with a high intake of total fat, individuals with the genotype Pro/Pro had a larger waist circumference.  A study by Lindi et al.  ADDIN EN.CITE (2003) examined the association of P12A before and after individuals were supplemented with omega-3 PUFAs for 3 months.  Prior to increased omega-3 consumption due to supplements, they did not observe an association between P12A and plasma triglycerides.  After 3 months, they observed that when total fat intake was < 37% and saturated fat intake was < 10%, presence of the Ala allele was associated with decreased triglycerides.  A recent study by Nelson et al. (2007) showed that when PUFA consumption was high, the Ala allele was associated with increased BMI.  When PUFA consumption was low, they did not find any association between P12A and BMI.  Finally, not all studies that have included fat intake have found an association with an obesity phenotype.  A study by Tai et al.  ADDIN EN.CITE (2004) did not find any associations between P12A when the P:S ratio was considered.

The results of our study with Yup’ik Eskimos seem to generally support the results of Robitaille et al. (2003) and Memisogle et al. (2003).  Both of these previous studies suggested that that a genotype of Pro/Pro resulted in a susceptibility to dietary fat intake.  Indeed, Yup’ik Eskimos with the genotype Pro/Pro who consumed a high intake of EPA and DHA had increased levels of adiponectin.  Also, although not significant, those with the Pro/Pro genotype who consumed a high intake of EPA and DHA showed a trend towards a higher BMI, body fat, waist circumference, sum of skin-folds, HDL cholesterol and lower triglycerides.  A similar trend was observed for Pro/Ala individuals who consumed a high intake of EPA and DHA.  However, the results of this study do not completely agree with the results and conclusions from Robitaille et al. (2003) who claimed that the Ala allele was protective.  It seems possible that for individuals with a Western diet, like those in the Robitaille et al. (2003) study who consume low amounts of EPA and DHA, Ala may be protective.  However in Yup’ik Eskimos who consume high amounts of PUFAs, Ala may not be beneficial.  In terms of BMI and sum of skin-folds the results of this study agree with Robitaille et al. (2003).  BMI and sum of skin-folds both decrease with a high fat diet when individuals have the Ala allele.  However, the effect on adiponectin due to the Ala allele is not protective.  In our study, individuals who consumed a high amount of PUFAs and who were homozygous for the Ala allele had decreased adiponectin levels.  Part of the difference in the results from this study and Robitaille et al. (2003) are due to Robitaille et al. (2003) not separating EPA and DHA out from total fat intake.  

The idea that the Pro allele of P12A seems to result in susceptibility to dietary fat intake, specifically of EPA and DHA, makes sense biologically.  In Yup’ik Eskimos it appears that high consumption of EPA and DHA has positive impacts on adiponectin and triglycerides, and HDL cholesterol when an individual has a copy of the Pro allele. Deeb et al.  ADDIN EN.CITE (1998) has suggested that the Ala allele resulted in lower transcription of PPARG target genes due to decreased binding at PPAR elements.  It is well known that fatty acids, including EPA and DHA, act as ligands for PPARG in order to activate transcription of target genes.  If having the Ala allele makes PPARG less sensitive to activation by fatty acids, like EPA and DHA, individuals with the Ala allele will not respond to changes in fat intake.  However, if the Pro allele is more sensitive to activation by fatty acids, like EPA and DHA, individuals with the Pro allele will respond greatly to changes in fat intake.  Biologically, when fat intake is low, activation of target genes by PPARG may be similar, irrespective of the Pro12Ala genotype.  However, when fat intake is high, activation of target genes by PPARG will be different depending on genotype, with individuals who have a copy of Pro being able to activate PPARG target genes more effectively than those with two copies of Ala.  The results of this study as well as those by Luan et al. (2001) and Lindi et al. (2003) support the idea that PUFAs are able to increase the transcription of PPARG, and the amount of PUFAs consumed should be included in association studies to determine the effects of P12A on obesity.

The frequency of the minor allele is an important factor in the ability of association studies to detect a true association.  Association studies may have less power to detect a true association to an allele with a low frequency than to one with a higher frequency.  Commonly, SNPs whose minor allele frequency is between 0.05 and 0.5 are good SNPs to choose to achieve reasonable power in a study (Pfeiffer and Gail, 2003).  In Yup’ik Eskimos, the minor allele of P12A, Ala (or G) has a frequency of 26%, and 47% of Yup’iks are carriers of the Ala allele.  Data from HapMap, available on the NCBI website (www.ncbi.nlm.nih.gov) show that Caucasians, who have an Ala frequency of about 7.5%, have the next highest frequency of the Ala allele in populations examined by HapMap.  Stumvoll and Haring (2002) cite Caucasians as having a 12% frequency of the Ala allele, and, consequently 22.5% of Caucasians were carriers of the Ala allele.  Overall, Yup’ik Eskimos have the highest frequency of the Ala allele compared to other populations previously studied.  





Table 4 13: Phenotype by H447 genotype and δ15N
The mean for each of the seven phenotypes investigated was determined based on H447H genotype and δ15N.  Low and high δ15N values were determined by finding the mean of δ15N.  High δ15N was any value greater than the mean δ15N, and low δ15N was any value equal to or less than the mean δ15N.  The row labeled N is the number of individuals with a specific genotype, GG, GA, or AA.  Numbers in parenthesis represent the standard deviation from the mean value.

rs3856806 (H447H G>A)	Low δ15N	High δ15N	Low δ15N	High δ15N	Low δ15N	High δ15N
 	GG	GG	GA	GA	AA	AA
N	299	209	205	158	36	18
BMI	26.4 (5.6)	28.6 (5.9)	27.2 (6.4)	28.2 (6.2)	28.4 (6.2)	28.3 (5.6)
BF	26.6 (10.6)	31.6 (9.9)	27.2 (11.5)	32.4 (10.5)	29.5 (11.1)	30.2 (10.1)
WC	86.8 (13.9)	93.5 (13.9)	89.2 (15.6)	93.2 (14.9)	91.6 (15.4)	93.6 (15.1)
Adiponectin	9.7 (5.2)	10.7 (5.7)	8.9 (5)	11.1 (6)	10.2 (6)	8.2 (4.3)
TG	91.7 (64.6)	83.5 (42)	85.5 (35.9)	78.5 (35.4)	84.6 (41.6)	79.2 (32.7)
HDL	55.9 (15)	66.2 (20)	55.5 (15.6)	67.1 (17.7)	59.4 (18.2)	65.1 (16.4)







Figure 4 3: Interaction graph for H447H (rs3856806) and δ15N on plasma adiponectin levels




Similar to P12A, the minor allele of H447H (C ) is more common in Yup’ik Eskimos compared to Caucasians in HapMap (25% vs 10% respectively).  However, unlike P12A, the frequency of the C allele in Yup’iks is similar to the frequency observed in Asian populations from HapMap.  Interestingly, although there were differences in the minor allele frequency for both H447H and P12A between Yup’iks and Caucasians, the frequency of the minor allele was similar within populations.  In other words, in Yup’iks, the frequencies of the minor allele of H447 and P12A are similar to one another, and in Caucasians the frequency of the minor allele of H447H and P12A were similar to one another.  

Previous studies have investigated both the association and GEI of H447H with obesity and diabetes phenotypes.  To my knowledge, only one study has investigated whether or not PUFAs modify the association of H447H with obesity phenotypes.  This study found the P:S ratio did not modify the effect of H447H on BMI or insulin  ADDIN EN.CITE (Tai et al., 2004).  Meirhaeghe et al.  ADDIN EN.CITE (1998) investigated the interaction between H447H and BMI on obesity phenotypes.  When they did not consider the interaction between H44H and BMI, they did not find an association between H447H and obesity phenotypes such as leptin.  However, when they considered BMI, they observed that levels of leptin where higher in obese individuals with the T allele.

Other investigators who have looked at the association of H447H with obesity phenotypes have found conflicting results.  Many have not found any association between H447H with obesity phenotypes  ADDIN EN.CITE (Larsen et al., 2005; Mohamed et al., 2007; Poulsen et al., 2003).  Others have found that the T allele has been associated with decreased BMI  ADDIN EN.CITE (Meirhaeghe et al., 1998) and increased BMI  ADDIN EN.CITE (Doney et al., 2002; Doney et al., 2004; Maeda et al., 2004; Tai et al., 2004; Valve et al., 1999).  Additionally, the T allele has been shown to be associated with decreased risk of T2D  ADDIN EN.CITE (Tai et al., 2004), decreased risk of cardiovascular disease,  ADDIN EN.CITE (Wang et al., 1999) increased waist circumference (Valve et al., 1999) and increased plasma triglycerides  ADDIN EN.CITE (Wang et al., 1999), decreased plasma triglycerides and VLDL  ADDIN EN.CITE (Tavares et al., 2005) and decreased HDL cholesterol (Rhee et al., 2006).  

Of the associations described in previous literature, it appears that the association between H447H and plasma triglycerides is inconsistent.  In Yup’ik Eskimos, a trend that did not reach significance was observed suggesting that individuals with a copy of the T allele who consumed high levels of EPA and DHA had lower TG levels compared to individuals with the same genotype who consumed low levels of EPA and DHA.  Additionally, individuals who were homozygous for CC and who consumed high levels of EPA and DHA had higher TG levels compared to individuals with the same genotype who consumed low levels of EPA and DHA.  Furthermore, H447H may also interact with EPA and DHA to influence HDL cholesterol.  A trend that did not reach significance was seen in Yup’ik Eskimos indicating that consumption of EPA and DHA increase HDL cholesterol for all genotypes (Table 4.13).

In other studies, a fairly consistent trend was observed towards individuals with a copy of the T allele having a higher BMI.  In Yup’ik Eskimos, a trend that did not reach significance was observed for all genotypes that consumption of high amounts of EPA and DHA may be associated with increased BMI, as well as body fat and waist circumference.  Therefore, the trend observed for measures of body mass in Yup’ik Eskimos seems to be consistent with previous studies.  However, previous studies that looked for associations between H447H and measures of diabetes, such as insulin resistance, do not appear to agree with trends observed in Yup’ik Eskimos.  In a study by Poulsen et al. ADDIN EN.CITE (2003), there was no association found between insulin resistance and H447H.  Also, another study by Tai et al.  ADDIN EN.CITE (2004) found no association between H447H and fasting insulin.  However, in Yup’iks, a GEI was observed between H447H and adiponectin, which is associated with insulin sensitivity.  Based on this study, it appears that H447H may be associated with insulin sensitivity because of the significant GEI observed with adiponectin.  Overall, based on the significant and insignificant results of this study, it appears that H447H may interact with EPA and DHA to influence numerous obesity phenotypes.  Although it appears that increased consumption of EPA and DHA may lead to increased measures of body mass, such as BMI and waist circumference, it also appears to increase levels of adiponectin and HDL cholesterol.  Both high levels of adiponectin and HDL cholesterol are considered to help reduce the risk of diabetes and cardiovascular disease. 

An interesting observation between the two SNPs in PPARG, P12A and H447H, that were influenced by δ15N is that in Yup’ik Eskimos they were in high LD (r2 =0.92).  Both P12A and H447H were originally identified in the same study that sequenced 26 diabetic Caucasians in 1997  ADDIN EN.CITE (Yen et al., 1997).  Many studies since than then that have investigated both P12A and H447H have shown LD between these two SNPs.  However, the amount of LD varied depending on the population studied  ADDIN EN.CITE (Doney et al., 2004; Tai et al., 2004; Valve et al., 1999).  Also, the study by Yen et al. (1997) showed that the allele frequencies of P12A and H447H were similar.  As described above, this is also true of the allele frequencies of P12A and H447H in Yup’ik Eskimos.  Many studies have investigated the importance of P12A on obesity and diabetes phenotypes.  However, it is still unclear whether P12A is a causative SNP.  Larsen et al.  ADDIN EN.CITE (2005) suggested that the phenotypic impact of P12A and H447H may be influenced by additional intragenic variants that are in LD.  A similar conclusion was suggested by Tai et al. (2004) who suggested that there may be another causal mutation in PPARG that is in LD with P12A and H447H.  They suggested that a study by Muller et al.  ADDIN EN.CITE (2003) that reported strong LD between P12A and rs12497191 in the Pima Indians of Arizona may be an example of a possible causal SNP in PPARG that is in LD with P12A.   

4.11 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA CO-ACTIVATOR 1 ALPHA (PPARGC1A)	
Table 4.14 shows the direction of the associations and GEIs observed in PPARGC1A.  For rs8192678 (G482S), the major allele, C (Gly), was associated with increased plasma adiponectin levels.  Additionally, the BMI was lower for individuals with either the genotype CC or CT who had higher levels of δ15N.  In a meta-analysis, the minor allele of this SNP, T (Ser) was found to not be associated with either BMI or fasting insulin (Barroso et al., 2006).  





Table 4 14: Direction of PPARGC1A associations and GEIs
Associations that were significant prior to Bonferroni are presented.  The column labeled, “p-value,” represents the overall significance of the SNP in the mixed model.  The column labeled, “B (standard error),” represents the B coefficient which indicates the direction of the association along with the standard error.  Finally, the column labeled, “B p-value,” represents the p-value of the B coefficient. Values with a * indicate the association is significant after Bonferroni correction.
























One of the main goals of this study was to identify whether PUFAs modify the association between SNPs in ADIPOQ, PPARG, and PPARGC1A and obesity phenotypes.  In regards to this goal, this study observed moderate evidence for GEIs between SNPs in PPARG and PPARGC1A.  In PPARG, there were GEIs observed between P12A and H447H with adiponectin.  The GEI between H447H and EPA and DHA that influenced adiponectin remained significant after Bonferroni.  Both these SNPs are in LD and have similar allele frequencies in Yup’ik Eskimos.  Although the GEI between P12A and adiponectin was not significant after Bonferroni correction for multiple testing, the GEI with P12A and PUFA intake has been observed previously in the literature.  The results of this study support that the association between P12A and H447H and obesity is modified by fat intake.  Additionally, GEIs were observed in PPARGC1A with rs2970847 with BMI, percent body fat, waist circumference, sum of skin-folds, plasma triglycerides, and HDL cholesterol.  One of these GEIs, between rs2970847 and sum of skin-folds remained significant after Bonferroni correction for multiple testing.  As studies by Luan et al. (2001) and Lindi et al. (2003) have shown, our results support the notion that if fat intake is not included in an association study, it will appear that there is no association between a SNP and a disease.  

An additional goal of this study was to see if SNPs in candidate genes for obesity were associated with obesity phenotypes.  In regards to this, the most novel and exciting results were observed.  The most significant results in this study were the associations identified between ADIPOQ SNP 1 and SNP 2 and plasma adiponectin levels in Yup’ik Eskimos.  Additionally, there was evidence of possible associations between both these SNPs and other obesity phenotypes.  Both of these SNPs were identified in Yup’ik Eskimos by re-sequencing all exons, intron-exon boundaries, and 5kb of 5’ flanking DNA in 30 un-related Yup’ik Eskimos.  Previously, 17 SNPs in ADIPOQ were examined in a smaller sample of Yup’iks and a large group of Caucasians and obtained marginally significant results.  These results suggested that additional SNPs should be genotyped in Yup’ik Eksimos (Boyer, pers. comm.).  Additionally, in this study, we also found that another SNP located upstream of ADIPOQ, -11391, was associated with HDL cholesterol and remained significant after Bonferroni correction for multiple testing.  When considering ADIPOQ, the results of this study support the idea that all SNPs within a candidate gene should be considered in order to determine whether or not the gene is involved in a disease. Both SNP 1 and 2 have relatively low allele frequencies (3-4%) and to our knowledge, no associations have been done with them for obesity in other populations.  Clearly, given the significance of our findings in Yup’ik Eskimos, it would be interesting to genotype SNPs 1 and 2 in larger population samples.  Overall, this study supports the idea that ADIPOQ plays a role in the etiology of obesity in Yup’ik Eskimos.
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24HR: 24 hour recall





BAT: Brown adipose tissue
BF: Body fat
BMI: Body mass index
CANHR: Center for Alaska Native Health Research
CBPR: Community based participatory research
CT: Computer-assisted tomography scanning
δ15N: Ratio of nitrogen 15 and nitrogen 14.





FFA: Free fatty acid
FFQ: Food frequency questionnaire
GEI: Gene by environment interaction
GWA: Genome wide association
HDL: HDL cholesterol
HMW: High molecular weight
HWE: Hardy Weinberg equilibirum
IBD: Identity by descent
LA: Linolic acid
LD: Linkage disequilibirum
MRI: Magnetic resonance imaging
n-3: omega-3 fatty acid
n-6: omega-6 fatty acid
NEFA: Non-esterified fatty acid
NHANES III: National health and nutrition examination survey three
P:S: Ratio of polyunsaturated fatty acids to saturated fatty acids
PBF: Percent body fat
PPARG: Peroxisome proliferator activated receptor gamma
PPARGC1A: Peroxisome proliferator activated receptor gamma coactivator one alpha
PUFAs: Polyunsaturated fatty acids
QTL: Quantitative trait loci
RBC: Red blood cell
RXR: Retinoid X receptor
SNP: Single nucleotide polymorphism
SOI: Subject of interest
SSF: Sum of skin-folds
T2D: Type II diabetes
TG: Plasma triglycerides
TZDs: Thiazolidinediones
WAT: White adipose tissue
WC: Waist circumference



































































































































































Marine eukaryotes produce EPA + DHA

EPA + DHA incorporated into consumer

EPA + DHA incorporated into higher trophic level consumers
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